[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1487
56. Thysell E, Surowiec I, Hörnberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikström P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One; 2010;5(12):e14175
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol.
  • BACKGROUND: Metastasis to the bone is one clinically important features of prostate cancer (PCa).
  • METHODOLOGY/PRINCIPAL FINDINGS: Metabolomics was applied for the study of PCa bone metastases (n = 20) in comparison with corresponding normal bone (n = 14), and furthermore of malignant (n = 13) and benign (n = 17) prostate tissue and corresponding plasma samples obtained from patients with (n = 15) and without (n = 13) diagnosed metastases and from men with benign prostate disease (n = 30).
  • Results were verified in a separate test set including metastatic and normal bone tissue from patients with other cancers (n = 7).
  • Significant differences were found between PCa bone metastases, bone metastases of other cancers, and normal bone.
  • Furthermore, we identified metabolites in primary tumor tissue and in plasma which were significantly associated with metastatic disease.
  • Immunohistochemical staining of PCa bone metastases showed intense staining of the low density lipoprotein receptor and variable levels of the scavenger receptor class B type 1 and 3-hydroxy-3-methylglutaryl-coenzyme reductase in tumor epithelial cells, indicating possibilities for influx and de novo synthesis of cholesterol.
  • [MeSH-minor] Biopsy. Bone and Bones / pathology. Computational Biology / methods. Gas Chromatography-Mass Spectrometry / methods. Humans. Immunohistochemistry / methods. Male. Neoplasm Metastasis. Prostatic Neoplasms / pathology. Sarcosine / metabolism. Tissue Distribution

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cholesterol.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer Prev. 2001 Dec;10(6):507-13 [11916349.001]
  • [Cites] PLoS One. 2009;4(9):e7075 [19763266.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12027-32 [14512514.001]
  • [Cites] Magn Reson Med. 2003 Nov;50(5):944-54 [14587005.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jan;36(1):39-77 [14592533.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Jul;24(7):1150-60 [15130918.001]
  • [Cites] Prog Clin Biol Res. 1981;75A:279-324 [6175978.001]
  • [Cites] Science. 1986 Apr 4;232(4746):34-47 [3513311.001]
  • [Cites] Prostate. 1992;20(2):151-8 [1549552.001]
  • [Cites] Magn Reson Med. 1992 May;25(1):140-7 [1375702.001]
  • [Cites] Magn Reson Med. 1993 Feb;29(2):149-57 [8429778.001]
  • [Cites] J Urol. 1993 Dec;150(6):2019-24 [7693985.001]
  • [Cites] JAMA. 1998 May 20;279(19):1542-7 [9605898.001]
  • [Cites] Anticancer Res. 1998 May-Jun;18(3A):1429-34 [9673351.001]
  • [Cites] J Urol. 1999 Jan;161(1):152-5 [10037388.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):959-68 [15776112.001]
  • [Cites] Anal Chem. 2005 Sep 1;77(17):5635-42 [16131076.001]
  • [Cites] Anal Chem. 2005 Dec 15;77(24):8086-94 [16351159.001]
  • [Cites] J Proteome Res. 2006 Jun;5(6):1407-14 [16739992.001]
  • [Cites] Urology. 2006 Jun;67(6):1205-11 [16765180.001]
  • [Cites] Curr Treat Options Oncol. 2006 Sep;7(5):355-62 [16904052.001]
  • [Cites] Mol Cancer Ther. 2006 Sep;5(9):2310-6 [16985065.001]
  • [Cites] Mol Endocrinol. 2006 Oct;20(10):2265-77 [16455816.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10795-804 [17108116.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 20;98(24):1819-25 [17179483.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):41-51 [17173048.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):256-69 [17384581.001]
  • [Cites] J Urol. 2007 Dec;178(6):2252-9 [17936845.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2213-7 [17971518.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2218-25 [17971519.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2226-32 [18006910.001]
  • [Cites] J Pharmacol Sci. 2008 Apr;106(4):536-41 [18431036.001]
  • [Cites] Trends Endocrinol Metab. 2008 May-Jun;19(4):113-21 [18356074.001]
  • [Cites] J Urol. 2008 Jun;179(6):2422-6 [18433783.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4447-54 [18519708.001]
  • [Cites] Mol Cancer. 2008;7:72 [18799019.001]
  • [Cites] Cancer Biomark. 2008;4(4-5):263-76 [18957715.001]
  • [Cites] Mol Cell Endocrinol. 2008 Nov 25;295(1-2):115-20 [18782595.001]
  • [Cites] Cancer Causes Control. 2008 Dec;19(10):1259-66 [18704722.001]
  • [Cites] J Proteome Res. 2009 Jan;8(1):352-61 [19063642.001]
  • [Cites] Cancer Treat Rev. 2009 Feb;35(1):1-8 [18778896.001]
  • [Cites] Nature. 2009 Feb 12;457(7231):910-4 [19212411.001]
  • [Cites] Am J Pathol. 2009 Mar;174(3):1017-26 [19179610.001]
  • [Cites] Cancer. 2009 Jul 1;115(13 Suppl):3058-67 [19544547.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2807-13 [19887582.001]
  • [Cites] Clin Exp Metastasis. 2009;26(7):781-7 [19526315.001]
  • [Cites] Endocr Relat Cancer. 2010 Dec;17(4):885-95 [20688881.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2227-31 [11956073.001]
  • (PMID = 21151972.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 97C5T2UQ7J / Cholesterol; Z711V88R5F / Sarcosine
  • [Other-IDs] NLM/ PMC2997052
  •  go-up   go-down


57. Rowe LA, Degtyareva N, Doetsch PW: DNA damage-induced reactive oxygen species (ROS) stress response in Saccharomyces cerevisiae. Free Radic Biol Med; 2008 Oct 15;45(8):1167-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At high levels, ROS can lead to impaired physiological function through cellular damage of DNA, proteins, lipids, and other macromolecules, which can lead to certain human pathologies including cancers, neurodegenerative disorders, and cardiovascular disease, as well as aging.
  • We find that when DNA damage is introduced into cells from exogenous or endogenous sources there is an increase in the amount of intracellular ROS which is not directly related to cell death.

  • COS Scholar Universe. author profiles.
  • Saccharomyces Genome Database. Saccharomyces Genome Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Cell Biol. 1997 Apr;9(2):240-6 [9069263.001]
  • [Cites] Eur J Cancer. 1996 Jan;32A(1):30-8 [8695238.001]
  • [Cites] J Immunol Methods. 1997 Mar 28;202(2):133-41 [9107302.001]
  • [Cites] EMBO J. 1997 Apr 1;16(7):1710-20 [9130715.001]
  • [Cites] J Cell Biol. 1997 Nov 3;139(3):729-34 [9348289.001]
  • [Cites] Anal Biochem. 1997 Nov 15;253(2):162-8 [9367498.001]
  • [Cites] Nitric Oxide. 1997 Apr;1(2):145-57 [9701053.001]
  • [Cites] Genes Cells. 1998 Aug;3(8):521-32 [9797454.001]
  • [Cites] Free Radic Biol Med. 1998 Nov 1;25(7):826-31 [9823548.001]
  • [Cites] EMBO J. 1998 Dec 15;17(24):7416-29 [9857197.001]
  • [Cites] Yeast. 1998 Dec;14(16):1511-27 [9885153.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):2929-35 [10082560.001]
  • [Cites] Cell Signal. 1999 Jan;11(1):1-14 [10206339.001]
  • [Cites] Mutat Res. 2005 Jan 6;569(1-2):13-27 [15603750.001]
  • [Cites] Gene. 2005 Jan 3;344:43-51 [15656971.001]
  • [Cites] Trends Cell Biol. 2005 Jun;15(6):319-26 [15953550.001]
  • [Cites] Annu Rev Microbiol. 2005;59:357-77 [16153173.001]
  • [Cites] Chem Biol Interact. 2006 Mar 10;160(1):1-40 [16430879.001]
  • [Cites] Apoptosis. 2007 May;12(5):1011-23 [17453165.001]
  • [Cites] Cell Signal. 2007 Sep;19(9):1807-19 [17570640.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Oct;8(10):813-24 [17848967.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Feb 4;243(1):13-9 [9473471.001]
  • [Cites] Oncogene. 1999 Nov 1;18(45):6104-11 [10557101.001]
  • [Cites] Mol Cell Biol. 1999 Dec;19(12):8302-13 [10567555.001]
  • [Cites] Science. 1999 Dec 3;286(5446):1897-905 [10583946.001]
  • [Cites] Mutat Res. 2000 Jun 30;451(1-2):39-51 [10915864.001]
  • [Cites] EMBO J. 2000 Oct 2;19(19):5157-66 [11013218.001]
  • [Cites] Nature. 2000 Nov 9;408(6809):239-47 [11089981.001]
  • [Cites] Redox Rep. 2000;5(5):277-85 [11145102.001]
  • [Cites] Apoptosis. 2000 Nov;5(5):415-8 [11256882.001]
  • [Cites] Curr Opin Hematol. 2002 Jan;9(1):11-7 [11753072.001]
  • [Cites] Physiol Rev. 2002 Jan;82(1):47-95 [11773609.001]
  • [Cites] Curr Genet. 2002 Jul;41(4):208-16 [12172961.001]
  • [Cites] Cell. 2002 Nov 15;111(4):471-81 [12437921.001]
  • [Cites] Microbiol Mol Biol Rev. 2002 Dec;66(4):630-70, table of contents [12456786.001]
  • [Cites] J Biol Chem. 2003 Jan 31;278(5):3170-5 [12419811.001]
  • [Cites] Mutat Res. 2003 Nov 27;532(1-2):227-43 [14643439.001]
  • [Cites] Biochimie. 2003 Nov;85(11):1083-99 [14726015.001]
  • [Cites] Nat Rev Immunol. 2004 Mar;4(3):181-9 [15039755.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):22585-94 [15020594.001]
  • [Cites] FEBS Lett. 2004 Jun 1;567(1):80-5 [15165897.001]
  • [Cites] Nucleic Acids Res. 2004;32(12):3712-23 [15254273.001]
  • [Cites] DNA Repair (Amst). 2004 Aug-Sep;3(8-9):1123-32 [15279801.001]
  • [Cites] Annu Rev Plant Biol. 2004;55:373-99 [15377225.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Nov;78(11):7124-8 [6947277.001]
  • [Cites] Genes Dev. 1989 Mar;3(3):283-92 [2542125.001]
  • [Cites] Genetics. 1989 May;122(1):19-27 [2659436.001]
  • [Cites] J Biol Chem. 1991 Jun 25;266(18):11632-9 [1646813.001]
  • [Cites] Arch Biochem Biophys. 1993 May;302(2):348-55 [8387741.001]
  • [Cites] J Leukoc Biol. 1994 Feb;55(2):253-8 [8301222.001]
  • [Cites] EMBO J. 1994 Feb 1;13(3):655-64 [8313910.001]
  • [Cites] Hypertension. 1995 Feb;25(2):155-61 [7843763.001]
  • [Cites] J Biol Chem. 1997 Mar 28;272(13):8370-9 [9079661.001]
  • (PMID = 18708137.001).
  • [ISSN] 0891-5849
  • [Journal-full-title] Free radical biology & medicine
  • [ISO-abbreviation] Free Radic. Biol. Med.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P01 ES011163; United States / NIEHS NIH HHS / ES / P01 ES011163-06A1; United States / NIEHS NIH HHS / ES / ES 011163
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Reactive Oxygen Species; 0 / Saccharomyces cerevisiae Proteins; 0 / Transcription Factors; 0 / YAP1 protein, S cerevisiae
  • [Other-IDs] NLM/ NIHMS74785; NLM/ PMC2643028
  •  go-up   go-down


58. Podgorski I, Linebaugh BE, Koblinski JE, Rudy DL, Herroon MK, Olive MB, Sloane BF: Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis. Am J Pathol; 2009 Sep;175(3):1255-69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bone metastasis is a hallmark of advanced prostate and breast cancers, yet the critical factors behind attraction of tumors to the skeleton have not been validated.
  • The coincident up-regulation of SPARC and cathepsin K occurred both in vivo in experimental prostate bone tumors, and in vitro in co-cultures of bone marrow stromal cells with PC3 prostate carcinoma cells.
  • PC3-bone marrow stromal cell interaction increased secretion and processing of SPARC, as did co-cultures of bone marrow stromal cells with two other cancer cell lines.
  • In addition, bone marrow stromal cells that were either deficient in cathepsin K or treated with cathepsin K inhibitors had significantly reduced secretion and cleavage of SPARC.
  • Increases in secretion of pro-inflammatory cytokines (ie, interleukin-6, -8) coincident with overexpression of cathepsin K suggest possible mechanisms by which this enzyme contributes to tumor progression in the bone.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urol Oncol. 2007 Sep-Oct;25(5):407-11 [17826661.001]
  • [Cites] Gene. 2007 Nov 15;403(1-2):151-8 [17897792.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):9894-902 [17942921.001]
  • [Cites] Cancer Biol Ther. 2007 Apr;6(4):618-9 [18027438.001]
  • [Cites] Cancer Metastasis Rev. 2008 Mar;27(1):41-55 [18071636.001]
  • [Cites] Science. 2008 Feb 1;319(5863):624-7 [18239127.001]
  • [Cites] Nutr Rev. 2007 Dec;65(12 Pt 2):S147-51 [18240539.001]
  • [Cites] Biochimie. 2008 Feb;90(2):208-26 [17935853.001]
  • [Cites] Biomed Pharmacother. 2008 Feb;62(2):130-5 [17728092.001]
  • [Cites] Autoimmunity. 2008 Apr;41(3):183-94 [18365831.001]
  • [Cites] Biochim Biophys Acta. 2008 Apr;1785(2):85-95 [18082147.001]
  • [Cites] Int J Biochem Cell Biol. 2008;40(6-7):1185-98 [18243768.001]
  • [Cites] J Cell Biochem. 2008 Jun 1;104(3):721-32 [18253934.001]
  • [Cites] Cancer Metastasis Rev. 2008 Sep;27(3):523-37 [18459035.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5357-67 [18765527.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):9050-9 [18974151.001]
  • [Cites] Drug Resist Updat. 2008 Dec;11(6):231-46 [18849185.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):679-91 [19213681.001]
  • [Cites] Med Oncol. 2009;26(1):10-5 [18461289.001]
  • [Cites] J Cell Biochem. 2009 Mar 1;106(4):563-9 [19170075.001]
  • [Cites] J Rheumatol. 1998 Oct;25(10):1887-94 [9779840.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13453-8 [9811821.001]
  • [Cites] J Biol Chem. 1998 Nov 27;273(48):32347-52 [9822715.001]
  • [Cites] J Clin Invest. 1999 Mar;103(5):731-8 [10074491.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1987-93 [10213511.001]
  • [Cites] J Rheumatol. 1999 Apr;26(4):791-9 [10229398.001]
  • [Cites] Arthritis Rheum. 1999 Aug;42(8):1588-93 [10446855.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4453-7 [10485497.001]
  • [Cites] Bone. 2005 Jan;36(1):159-72 [15664014.001]
  • [Cites] Endocrinology. 2005 Apr;146(4):1727-36 [15637291.001]
  • [Cites] Neoplasia. 2005 Mar;7(3):207-23 [15799821.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5123-32 [15958556.001]
  • [Cites] J Biol Chem. 2005 Aug 5;280(31):28370-81 [15929988.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7370-7 [16103089.001]
  • [Cites] Int J Biochem Cell Biol. 1999 Dec;31(12):1363-6 [10641790.001]
  • [Cites] Br J Cancer. 2000 Feb;82(4):858-64 [10732759.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1140-9 [10741745.001]
  • [Cites] Prostate. 2000 Jul 1;44(2):91-103 Jul 1;44(2) [10881018.001]
  • [Cites] J Exp Med. 2000 Sep 18;192(6):789-99 [10993910.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):532-7 [11212246.001]
  • [Cites] Matrix Biol. 2001 Jan;19(8):816-27 [11223341.001]
  • [Cites] J Bone Miner Res. 2001 Aug;16(8):1444-52 [11499867.001]
  • [Cites] J Bone Miner Res. 2001 Aug;16(8):1486-95 [11499871.001]
  • [Cites] Mol Carcinog. 2001 Oct;32(2):84-91 [11746820.001]
  • [Cites] J Natl Cancer Inst. 2002 Jan 2;94(1):17-25 [11773278.001]
  • [Cites] J Pathol. 2002 Mar;196(3):254-65 [11857487.001]
  • [Cites] J Cell Physiol. 2003 Jan;194(1):71-9 [12447991.001]
  • [Cites] J Bone Miner Res. 2003 Feb;18(2):222-30 [12568399.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):37849-57 [12867428.001]
  • [Cites] J Biol Chem. 2003 Oct 3;278(40):39044-50 [12885781.001]
  • [Cites] Histochem Cell Biol. 2003 Nov;120(5):391-400 [14600836.001]
  • [Cites] Histol Histopathol. 2004 Jan;19(1):189-99 [14702187.001]
  • [Cites] J Cell Biochem. 2004 Jul 1;92(4):679-90 [15211566.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):17-32 [15261139.001]
  • [Cites] Int J Cancer. 1978 Mar 15;21(3):274-81 [631930.001]
  • [Cites] Invest Urol. 1979 Jul;17(1):16-23 [447482.001]
  • [Cites] Anal Biochem. 1983 Jun;131(2):538-47 [6193739.001]
  • [Cites] J Cell Biol. 1994 May;125(4):929-43 [7514608.001]
  • [Cites] J Clin Invest. 1994 Sep;94(3):1012-8 [8083342.001]
  • [Cites] J Biol Chem. 1996 May 24;271(21):12517-24 [8647860.001]
  • [Cites] Science. 1996 Aug 30;273(5279):1236-8 [8703060.001]
  • [Cites] Oncol Res. 1996;8(2):63-7 [8859776.001]
  • [Cites] J Biol Chem. 1997 Apr 4;272(14):9237-43 [9083057.001]
  • [Cites] Genomics. 1997 Apr 15;41(2):169-76 [9143491.001]
  • [Cites] J Cell Physiol. 1997 Dec;173(3):327-34 [9369945.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5386-90 [9393764.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1395-9 [9537238.001]
  • [Cites] Biochem J. 1998 May 1;331 ( Pt 3):727-32 [9560298.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2209-16 [9605768.001]
  • [Cites] Anal Chem. 2005 Nov 1;77(21):6765-71 [16255572.001]
  • [Cites] Cell. 2006 Jan 27;124(2):263-6 [16439202.001]
  • [Cites] Bioorg Med Chem Lett. 2006 Apr 1;16(7):1985-9 [16413777.001]
  • [Cites] J Immunol. 2006 May 15;176(10):5825-32 [16670288.001]
  • [Cites] Am J Clin Pathol. 2006 Jun;125(6):847-54 [16690483.001]
  • [Cites] Nat Med. 2006 Jun;12(6):657-64 [16715089.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7968-75 [16912171.001]
  • [Cites] Prostate. 2006 Sep 1;66(12):1311-8 [16705739.001]
  • [Cites] Nat Rev Cancer. 2006 Oct;6(10):764-75 [16990854.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6213s-6216s [17062703.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2649-56 [17363585.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3646-53 [17440076.001]
  • [Cites] Clin Sci (Lond). 2007 Jun;112(11):567-75 [17241109.001]
  • [Cites] Neurosci Lett. 2007 May 29;419(2):172-7 [17490812.001]
  • [Cites] Biochem Soc Trans. 2007 Aug;35(Pt 4):701-3 [17635127.001]
  • (PMID = 19700761.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA056586; United States / NIEHS NIH HHS / ES / P30 ES006639; United States / NCI NIH HHS / CA / P30 CA022453; United States / NCI NIH HHS / CA / R01 CA 56586; United States / NCI NIH HHS / CA / P30 CA 22453; United States / NIEHS NIH HHS / ES / P30 ES 06639; United States / NCRR NIH HHS / RR / U54 RR020843
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / Interleukin-8; 0 / Osteonectin; EC 3.4.22.38 / Cathepsin K
  • [Other-IDs] NLM/ PMC2731144
  •  go-up   go-down


59. Shorter J: Emergence and natural selection of drug-resistant prions. Mol Biosyst; 2010 Jul;6(7):1115-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Drug resistance is a refractory barrier in the battle against many fatal diseases caused by rapidly evolving agents, including HIV, apicomplexans and specific cancers.
  • Once in motion, this chain reaction of conformational replication can deplete all non-prion copies of a protein.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. QUINACRINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • Saccharomyces Genome Database. Saccharomyces Genome Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neural Transm (Vienna). 2006 Sep;113(9):1243-51 [16362635.001]
  • [Cites] Hum Mol Genet. 2006 Sep 15;15(18):2743-51 [16893904.001]
  • [Cites] Science. 2006 Sep 15;313(5793):1604-10 [16902091.001]
  • [Cites] Science. 2006 Sep 22;313(5794):1781-4 [16990547.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Oct;50(10):3447-9 [17005828.001]
  • [Cites] Science. 2006 Oct 6;314(5796):133-6 [17023660.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 24;103(43):15806-11 [17038504.001]
  • [Cites] N Engl J Med. 2006 Nov 23;355(21):2254-5 [17124027.001]
  • [Cites] Lancet. 2006 Dec 9;368(9552):2061-7 [17161728.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):19105-10 [17142317.001]
  • [Cites] J Mol Biol. 2007 Jan 19;365(3):773-82 [17097676.001]
  • [Cites] Adv Protein Chem. 2006;73:235-82 [17190616.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19754-9 [17170131.001]
  • [Cites] Genes Dev. 2007 Jan 15;21(2):195-205 [17234885.001]
  • [Cites] Neuron. 2007 Feb 1;53(3):325-35 [17270731.001]
  • [Cites] Trends Mol Med. 2007 Feb;13(2):64-71 [17207661.001]
  • [Cites] FEBS J. 2007 Feb;274(3):588-605 [17288548.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2649-54 [17299036.001]
  • [Cites] Nature. 2007 Apr 5;446(7136):668-71 [17410176.001]
  • [Cites] Science. 2007 May 4;316(5825):750-4 [17478722.001]
  • [Cites] Trends Biochem Sci. 2007 May;32(5):217-24 [17412596.001]
  • [Cites] PLoS Pathog. 2007 Mar;3(3):e31 [17352534.001]
  • [Cites] JAMA. 2007 May 23;297(20):2264-77 [17519416.001]
  • [Cites] Nature. 2007 May 24;447(7143):453-7 [17468747.001]
  • [Cites] Nature. 2007 May 31;447(7144):556-61 [17495929.001]
  • [Cites] EMBO J. 2007 Jul 11;26(13):3169-79 [17581637.001]
  • [Cites] Nature. 2007 Sep 13;449(7159):233-7 [17767153.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17204-9 [17940007.001]
  • [Cites] Theor Popul Biol. 2007 Dec;72(4):560-75 [17915273.001]
  • [Cites] Science. 2007 Nov 9;318(5852):930-6 [17991853.001]
  • [Cites] Nat Neurosci. 2007 Dec;10(12):1587-93 [17965711.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 27;104(48):19023-8 [18024584.001]
  • [Cites] Nature. 2007 Dec 13;450(7172):1001-9 [18075579.001]
  • [Cites] Cell. 2007 Dec 14;131(6):1059-71 [18083097.001]
  • [Cites] Neurosignals. 2008;16(1):63-74 [18097161.001]
  • [Cites] Science. 2007 Dec 21;318(5858):1900-3 [18096801.001]
  • [Cites] Nat Rev Microbiol. 2008 Mar;6(3):187-98 [18246082.001]
  • [Cites] Science. 2008 Feb 15;319(5865):916-9 [18276881.001]
  • [Cites] Nat Chem Biol. 2008 Mar;4(3):197-9 [18223646.001]
  • [Cites] Nat Genet. 2008 Apr;40(4):460-5 [18362884.001]
  • [Cites] Nat Med. 2008 May;14(5):504-6 [18391962.001]
  • [Cites] Nat Med. 2008 May;14(5):501-3 [18391963.001]
  • [Cites] Neurology. 2008 May 13;70(20):1916-25 [18474848.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 20;105(20):7159-64 [18480256.001]
  • [Cites] J Chem Inf Model. 2008 May;48(5):1055-73 [18505239.001]
  • [Cites] Nat Struct Mol Biol. 2008 Jun;15(6):558-66 [18511942.001]
  • [Cites] Nat Struct Mol Biol. 2008 Jun;15(6):544-6 [18523464.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10595-600 [18647832.001]
  • [Cites] Mol Biosyst. 2008 Sep;4(9):895-901 [18704227.001]
  • [Cites] Cell. 2008 Sep 5;134(5):769-81 [18775310.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13626-31 [18757733.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):13977-81 [18779569.001]
  • [Cites] J Neurochem. 2008 Oct;107(1):218-29 [18691383.001]
  • [Cites] EMBO J. 2008 Oct 22;27(20):2712-24 [18833196.001]
  • [Cites] J Am Chem Soc. 2008 Nov 12;130(45):14990-5001 [18937465.001]
  • [Cites] Exp Gerontol. 2008 Dec;43(12):1086-93 [18799131.001]
  • [Cites] Trends Genet. 2008 Dec;24(12):604-12 [18992957.001]
  • [Cites] PLoS Biol. 2008 Nov 25;6(11):e294 [19067491.001]
  • [Cites] Nat Cell Biol. 2008 Sep;10(9):1069-75 [19160487.001]
  • [Cites] Prion. 2007 Jan-Mar;1(1):48-52 [19164923.001]
  • [Cites] Prion. 2007 Apr-Jun;1(2):83-93 [19164918.001]
  • [Cites] Nat Cell Biol. 2009 Feb;11(2):219-25 [19151706.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2818-23 [19196973.001]
  • [Cites] Prion. 2008 Oct-Dec;2(4):135-40 [19242125.001]
  • [Cites] Nat Cell Biol. 2009 Mar;11(3):328-36 [19198598.001]
  • [Cites] Nat Cell Biol. 2009 Mar;11(3):344-9 [19219034.001]
  • [Cites] Lancet Neurol. 2009 Apr;8(4):334-44 [19278902.001]
  • [Cites] Cell. 2009 Apr 3;137(1):146-58 [19345193.001]
  • [Cites] J Biol Chem. 2009 May 8;284(19):12845-52 [19282288.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 May 5;106(18):7443-8 [19376973.001]
  • [Cites] J Biol Chem. 2009 May 22;284(21):14386-95 [19329794.001]
  • [Cites] Annu Rev Biochem. 2009;78:959-91 [19298183.001]
  • [Cites] Nat Struct Mol Biol. 2009 Jun;16(6):598-605 [19491937.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9033-8 [19451623.001]
  • [Cites] PLoS Genet. 2009 Jun;5(6):e1000517 [19521499.001]
  • [Cites] Nature. 2009 Jun 18;459(7249):924-5 [19536253.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jun 16;106(24):9679-84 [19487684.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Aug 14;386(1):257-62 [19523444.001]
  • [Cites] Folia Neuropathol. 2009;47(2):104-13 [19618334.001]
  • [Cites] Biochemistry. 2009 Aug 18;48(32):7732-45 [19580328.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):13010-5 [19651612.001]
  • [Cites] FEBS Lett. 2009 Aug 20;583(16):2618-22 [19482025.001]
  • [Cites] Nat Struct Mol Biol. 2009 Sep;16(9):973-8 [19684598.001]
  • [Cites] Trends Genet. 2009 Sep;25(9):395-403 [19717203.001]
  • [Cites] Chem Biol. 2009 Sep 25;16(9):943-50 [19778722.001]
  • [Cites] Nature. 2009 Sep 24;461(7263):529-32 [19741608.001]
  • [Cites] FASEB J. 2009 Oct;23(10):3315-24 [19487308.001]
  • [Cites] Nat Chem Biol. 2009 Dec;5(12):936-46 [19915541.001]
  • [Cites] Cell Cycle. 2009 Dec;8(23):3960-70 [19901558.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):20051-6 [19892735.001]
  • [Cites] PLoS Pathog. 2009 Nov;5(11):e1000673 [19956709.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20417-22 [19915150.001]
  • [Cites] Cell. 2009 Dec 11;139(6):1157-69 [20005808.001]
  • [Cites] J Biol Chem. 2009 Dec 18;284(51):35543-55 [19840945.001]
  • [Cites] PLoS One. 2009;4(12):e8221 [20011040.001]
  • [Cites] Neuron. 2009 Dec 24;64(6):783-90 [20064386.001]
  • [Cites] Nature. 2010 Jan 21;463(7279):353-5 [20090752.001]
  • [Cites] Genetics. 2010 Feb;184(2):393-400 [19917766.001]
  • [Cites] PLoS Pathog. 2010 Jan;6(1):e1000736 [20107515.001]
  • [Cites] Biochem Cell Biol. 2010 Feb;88(1):1-13 [20130674.001]
  • [Cites] Cell. 2010 Feb 5;140(3):421-35 [20144764.001]
  • [Cites] EMBO J. 2010 Feb 17;29(4):782-94 [20057357.001]
  • [Cites] Science. 2010 Feb 26;327(5969):1132-5 [20110469.001]
  • [Cites] Mol Cell. 2010 Feb 26;37(4):541-50 [20188672.001]
  • [Cites] Nat Methods. 2010 Mar;7(3):237-42 [20154676.001]
  • [Cites] Trends Cell Biol. 2010 Mar;20(3):125-33 [20071174.001]
  • [Cites] Dis Model Mech. 2010 Mar-Apr;3(3-4):194-208 [20038714.001]
  • [Cites] J Virol. 2010 Apr;84(7):3408-12 [20032192.001]
  • [Cites] J Cell Sci. 2010 Apr 15;123(Pt 8):1191-201 [20356930.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6281-5 [20304795.001]
  • [Cites] Biochem J. 2010 May 15;428(1):95-101 [20196773.001]
  • [Cites] Biochemistry. 1996 Apr 30;35(17):5528-37 [8611544.001]
  • [Cites] Genetics. 1996 Dec;144(4):1375-86 [8978027.001]
  • [Cites] Cell. 1997 May 16;89(4):495-8 [9160741.001]
  • [Cites] Science. 1997 Jun 27;276(5321):2045-7 [9197268.001]
  • [Cites] Cell. 1997 Aug 8;90(3):549-58 [9267034.001]
  • [Cites] Nature. 1997 Aug 28;388(6645):839-40 [9278044.001]
  • [Cites] Neurobiol Aging. 1997 Jul-Aug;18(4):351-7 [9330961.001]
  • [Cites] Genetics. 1997 Oct;147(2):507-19 [9335589.001]
  • [Cites] Annu Rev Microbiol. 1997;51:151-78 [9343347.001]
  • [Cites] Cell. 1998 May 1;93(3):301-3 [9590160.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 26;95(11):6469-73 [9600990.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Jun;57(6):588-601 [9630238.001]
  • [Cites] Nat Med. 1998 Oct;4(10):1157-65 [9771749.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1318-20 [9809558.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13363-83 [9811807.001]
  • [Cites] J Gen Virol. 1999 Jan;80 ( Pt 1):11-4 [9934677.001]
  • [Cites] EMBO J. 1999 Apr 1;18(7):1974-81 [10202160.001]
  • [Cites] Chem Biol. 2004 Nov;11(11):1513-21 [15556002.001]
  • [Cites] J Biol Chem. 2004 Dec 10;279(50):52319-23 [15448141.001]
  • [Cites] Nature. 2004 Dec 16;432(7019):824-8 [15602547.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):315-20 [15630094.001]
  • [Cites] Science. 2005 Jan 14;307(5707):262-5 [15653506.001]
  • [Cites] Nat Rev Drug Discov. 2005 Jan;4(1):71-8 [15688074.001]
  • [Cites] J Biol Chem. 2005 Mar 4;280(9):7800-7 [15632170.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3395-400 [15705718.001]
  • [Cites] J Biol Chem. 2005 Mar 11;280(10):8808-12 [15618222.001]
  • [Cites] Anal Biochem. 2005 Apr 1;339(1):165-73 [15766724.001]
  • [Cites] Cell. 2005 Apr 22;121(2):195-206 [15851027.001]
  • [Cites] Nat Rev Genet. 2005 Jun;6(6):435-50 [15931169.001]
  • [Cites] Science. 2005 Jun 3;308(5727):1435-9 [15933194.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):765-72 [15944694.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):773-8 [15944695.001]
  • [Cites] NeuroRx. 2005 Jan;2(1):3-14 [15717053.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10165-70 [16006506.001]
  • [Cites] Neurosci Lett. 2005 Nov 11;388(2):106-11 [16039063.001]
  • [Cites] EMBO J. 2005 Sep 7;24(17):3082-92 [16096644.001]
  • [Cites] Nature. 2005 Sep 8;437(7056):262-5 [16148935.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15477-82 [16223878.001]
  • [Cites] Nature. 2004 Sep 9;431(7005):184-7 [15311209.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 5;101(40):14326-32 [15388848.001]
  • [Cites] Science. 2004 Oct 29;306(5697):865-9 [15514157.001]
  • [Cites] Nature. 1967 May 20;214(5090):764-6 [4963878.001]
  • [Cites] Genetics. 1981 Aug;98(4):691-711 [7037537.001]
  • [Cites] Science. 1982 Apr 9;216(4542):136-44 [6801762.001]
  • [Cites] J Biol Chem. 1982 Jul 25;257(14):7936-9 [6806288.001]
  • [Cites] Science. 1982 Dec 24;218(4579):1309-11 [6815801.001]
  • [Cites] Cell. 1983 Dec;35(2 Pt 1):349-58 [6418385.001]
  • [Cites] Biochem Biophys Res Commun. 1984 May 16;120(3):885-90 [6375662.001]
  • [Cites] Cell. 1985 Apr;40(4):735-46 [2859120.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Jun;82(12):4245-9 [3159021.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jul;83(13):4913-7 [3088567.001]
  • [Cites] J Gen Virol. 1987 Jan;68 ( Pt 1):79-89 [3100717.001]
  • [Cites] Science. 1991 Feb 8;251(4994):675-8 [1899488.001]
  • [Cites] Cell. 1993 Jul 2;73(7):1339-47 [8100741.001]
  • [Cites] Nat Genet. 1993 Aug;4(4):393-7 [8401588.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):10962-6 [7902575.001]
  • [Cites] Science. 1994 Apr 22;264(5158):566-9 [7909170.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2944-8 [7708753.001]
  • [Cites] Science. 1995 May 12;268(5212):880-4 [7754373.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15871-6 [16247008.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17342-7 [16293696.001]
  • [Cites] J Virol. 2006 Jan;80(2):1044-6 [16379006.001]
  • [Cites] Cancer Cell. 2006 Feb;9(2):133-46 [16473280.001]
  • [Cites] PLoS Biol. 2006 Jan;4(1):e6 [16300414.001]
  • [Cites] J Cell Sci. 1995 Apr;108 ( Pt 4):1617-27 [7615680.001]
  • [Cites] Nature. 1996 Jan 25;379(6563):339-43 [8552188.001]
  • [Cites] Biochemistry. 2006 May 16;45(19):6085-94 [16681381.001]
  • [Cites] Annu Rev Biochem. 2006;75:333-66 [16756495.001]
  • [Cites] Drug Metab Dispos. 2006 Jul;34(7):1136-44 [16581945.001]
  • [Cites] Science. 2006 Jul 7;313(5783):92-4 [16825570.001]
  • [Cites] Science. 2006 Jul 7;313(5783):94-7 [16825571.001]
  • [Cites] Mol Cell. 2006 Aug 4;23(3):425-38 [16885031.001]
  • [Cites] Nature. 2006 Aug 3;442(7102):585-9 [16810177.001]
  • [Cites] Brain. 2006 Sep;129(Pt 9):2241-65 [16816391.001]
  • [Cites] N Engl J Med. 1999 Dec 16;341(25):1865-73 [10601505.001]
  • [Cites] Mol Cell. 2000 Jan;5(1):163-72 [10678178.001]
  • [Cites] Cell. 2000 Mar 31;101(1):57-66 [10778856.001]
  • [Cites] J Virol. 2000 May;74(10):4894-7 [10775631.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4897-902 [10781096.001]
  • [Cites] Science. 2000 Aug 25;289(5483):1317-21 [10958771.001]
  • [Cites] Nature. 2000 Sep 28;407(6803):477-83 [11028992.001]
  • [Cites] Neuroscience. 2000;100(4):677-80 [11036200.001]
  • [Cites] Mol Cell Biol. 2000 Dec;20(23):8916-22 [11073991.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2000 Nov 29;355(1403):1669-76 [11127914.001]
  • [Cites] Curr Biol. 2001 Mar 6;11(5):366-9 [11267875.001]
  • [Cites] Yeast. 2001 Apr;18(6):489-97 [11284005.001]
  • [Cites] Mol Microbiol. 2001 Jun;40(6):1357-69 [11442834.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9836-41 [11504948.001]
  • [Cites] Nat Struct Biol. 2001 Nov;8(11):958-62 [11685242.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):45160-7 [11574536.001]
  • [Cites] Science. 2002 Feb 1;295(5556):851-5 [11823641.001]
  • [Cites] Curr Biol. 2002 Apr 2;12(7):523-30 [11937020.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5253-60 [11959975.001]
  • [Cites] Nat Struct Biol. 2002 May;9(5):389-96 [11938354.001]
  • [Cites] Nat Med. 2002 May;8(5):485-92 [11984593.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 28;99(11):7402-7 [12032295.001]
  • [Cites] Neuron. 2002 Jun 13;34(6):921-32 [12086640.001]
  • [Cites] Ann Neurol. 2002 Oct;52(4):503-6 [12325081.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1185-6 [12411925.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99 Suppl 4:16446-53 [12461168.001]
  • [Cites] Neurobiol Aging. 2003 Mar-Apr;24(2):197-211 [12498954.001]
  • [Cites] Science. 2003 Jan 31;299(5607):713-6 [12560553.001]
  • [Cites] Science. 2003 Apr 18;300(5618):486-9 [12702875.001]
  • [Cites] J Cell Biol. 2003 May 12;161(3):521-33 [12732614.001]
  • [Cites] J Virol. 2003 Aug;77(15):8462-9 [12857915.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):9034-8 [12853572.001]
  • [Cites] Nature. 2003 Jul 31;424(6948):549-52 [12891357.001]
  • [Cites] Evolution. 2003 Jul;57(7):1498-512 [12940355.001]
  • [Cites] Nat Biotechnol. 2003 Sep;21(9):1075-81 [12910243.001]
  • [Cites] J Virol. 2003 Oct;77(19):10288-94 [12970413.001]
  • [Cites] Nature. 2003 Oct 30;425(6961):957-62 [14562059.001]
  • [Cites] Science. 2003 Oct 31;302(5646):871-4 [14593181.001]
  • [Cites] J Biol Chem. 2003 Dec 5;278(49):49636-43 [14507919.001]
  • [Cites] J Theor Biol. 2004 Jan 21;226(2):205-14 [14643190.001]
  • [Cites] Cell. 2003 Dec 26;115(7):879-91 [14697205.001]
  • [Cites] Proc Biol Sci. 2003 Dec 22;270(1533):2573-8 [14728779.001]
  • [Cites] Ann Neurol. 2004 Feb;55(2):164-73 [14755719.001]
  • [Cites] J Biol Chem. 2004 Feb 27;279(9):7378-83 [14668331.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2287-92 [14983002.001]
  • [Cites] Biochemistry. 2004 Mar 16;43(10):2879-87 [15005623.001]
  • [Cites] Dement Geriatr Cogn Disord. 2004;17(3):158-63 [14739538.001]
  • [Cites] Nature. 2004 Mar 18;428(6980):319-23 [15029195.001]
  • [Cites] Nature. 2004 Mar 18;428(6980):323-8 [15029196.001]
  • [Cites] Biochim Biophys Acta. 2004 May 6;1698(2):131-53 [15134647.001]
  • [Cites] Nat Genet. 2004 Jun;36(6):585-95 [15146184.001]
  • [Cites] Annu Rev Biochem. 2004;73:617-56 [15189155.001]
  • [Cites] Science. 2004 Jun 18;304(5678):1793-7 [15155912.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9683-8 [15210972.001]
  • [Cites] J Gen Virol. 2004 Aug;85(Pt 8):2479-83 [15269390.001]
  • [Cites] Science. 2004 Jul 30;305(5684):673-6 [15286374.001]
  • (PMID = 20422111.001).
  • [ISSN] 1742-2051
  • [Journal-full-title] Molecular bioSystems
  • [ISO-abbreviation] Mol Biosyst
  • [Language] ENG
  • [Grant] United States / NIH HHS / OD / DP2 OD002177-01; United States / NIH HHS / OD / 1DP2OD002177-01; United States / NINDS NIH HHS / NS / R21 NS067354-02; United States / NINDS NIH HHS / NS / R21 NS067354-01; United States / NIH HHS / OD / DP2 OD002177; United States / NINDS NIH HHS / NS / 1R21NS067354-0110; United States / NINDS NIH HHS / NS / R21 NS067354
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Prions; H0C805XYDE / Quinacrine; RSY4RK37KQ / Swainsonine
  • [Number-of-references] 250
  • [Other-IDs] NLM/ NIHMS232340; NLM/ PMC2936920
  •  go-up   go-down


60. Goel S, Desai K, Karri S, Gollamudi R, Chaudhary I, Bulgaru A, Kaubisch A, Goldberg G, Einstein M, Camacho F, Baker S, Mani S: Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers. Invest New Drugs; 2007 Jun;25(3):237-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers.
  • BACKGROUND: Capecitabine and irinotecan have demonstrated in vitro synergistic anti-cancer activity, and both are substrates for carboxyl esterases (CES).
  • Responses were observed in 9 of 35 (5 of 9 ovarian cancer) evaluable patients.
  • The combination of irinotecan and capecitabine is safe and well tolerated at 100/2000, and warrants further evaluation in ovarian and breast cancer.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2005 Mar 3;352(9):895-904 [15745980.001]
  • [Cites] JAMA. 2004 Nov 3;292(17):2130-40 [15523074.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3589-96 [12552961.001]
  • [Cites] J Clin Oncol. 2001 Nov 1;19(21):4097-106 [11689577.001]
  • [Cites] Anal Biochem. 2004 May 1;328(1):84-6 [15081912.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4983-91 [14581373.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 1;98 (3):219 [16449682.001]
  • [Cites] Ann Oncol. 2005 Jul;16(7):1123-32 [15939714.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3801-7 [11559717.001]
  • [Cites] Am J Clin Oncol. 2002 Oct;25(5):528-34 [12393999.001]
  • [Cites] Ann Oncol. 2003 Nov;14(11):1682-7 [14581279.001]
  • [Cites] Ann Oncol. 2002 May;13(5):797-801 [12075751.001]
  • [Cites] Br J Cancer. 2005 Mar 14;92 (5):820-6 [15756252.001]
  • [Cites] Br J Cancer. 2006 Apr 10;94(7):964-8 [16552436.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2282-92 [11304782.001]
  • [Cites] Clin Ther. 2005 Jan;27(1):23-44 [15763604.001]
  • [Cites] Drug Metab Dispos. 2004 Oct;32(10):1103-10 [15269188.001]
  • [Cites] Gynecol Oncol. 2004 May;93(2):417-21 [15099955.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):291-7 [12525521.001]
  • [Cites] N Engl J Med. 2005 Jun 30;352(26):2696-704 [15987918.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):1980-1 [16648497.001]
  • [Cites] N Engl J Med. 2000 Sep 28;343 (13):905-14 [11006366.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2038-43 [16648503.001]
  • [Cites] Clin Colorectal Cancer. 2005 Jan;4(5):336-43 [15663838.001]
  • [Cites] Can J Cardiol. 2006 Mar 1;22(3):251-3 [16520857.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;45(4):291-7 [10755317.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2812-23 [12065558.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3177 [12915613.001]
  • [Cites] Anticancer Res. 2005 Jul-Aug;25(4):2985-90 [16080556.001]
  • (PMID = 17195945.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / K12 RR017672
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RPR 121056; 0 / SN38-Glu; 0H43101T0J / irinotecan; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; EC 3.1.1.1 / Carboxylesterase; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


61. Vickers AJ, Cronin AM, Roobol MJ, Savage CJ, Peltola M, Pettersson K, Scardino PT, Schröder FH, Lilja H: A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin Cancer Res; 2010 Jun 15;16(12):3232-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.
  • PURPOSE: We have developed a statistical prediction model for prostate cancer based on four kallikrein markers in blood: total, free, and intact prostate-specific antigen (PSA), and kallikrein-related peptidase 2 (hK2).
  • EXPERIMENTAL DESIGN: A total of 1,501 previously screened men with elevated PSA underwent initial biopsy during rounds 2 and 3 of the European Randomized Study of Screening for Prostate Cancer, Rotterdam, with 388 cancers diagnosed.
  • Similar statistically significant enhancements were seen for high-grade cancer.
  • Applying the model with a cutoff of 20% cancer risk as the criterion for biopsy would reduce the biopsy rate by 362 for every 1,000 men with elevated PSA.
  • Although diagnosis would be delayed for 47 cancers, these would be predominately low-stage and low-grade (83% Gleason 6 T(1c)).


62. Ataee R, Ajdary S, Zarrindast M, Rezayat M, Hayatbakhsh MR: Anti-mitogenic and apoptotic effects of 5-HT1B receptor antagonist on HT29 colorectal cancer cell line. J Cancer Res Clin Oncol; 2010 Oct;136(10):1461-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-mitogenic and apoptotic effects of 5-HT1B receptor antagonist on HT29 colorectal cancer cell line.
  • PURPOSE: There is lack of evidence about impact of 5-HT receptors on colorectal cancers.
  • The current study was designed to investigate the role of serotonin and its receptors in colorectal cancer cell line and tissues.
  • METHODS: In cell cultures, we investigated the effects of 5-HT and 5-HT(1A,1B,1D) agonists and antagonists on proliferation of HT29 cells.
  • RESULTS: Our data indicated that 5-HT(1B) receptor was fully expressed in HT29 cell line and tumor tissues.
  • CONCLUSIONS: The findings of this study provide evidence for the potential role of 5-HT(1B) receptor in colorectal cancer.
  • Further investigation is required to explore the effect of receptor antagonists on the prevention, prognosis and treatment of patients with colorectal cancer.
  • [MeSH-minor] Blotting, Western. Cell Cycle / drug effects. Cell Proliferation / drug effects. HT29 Cells. Humans. Immunohistochemistry. Receptor, Serotonin, 5-HT1B / physiology. Serotonin / physiology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res Treat. 2001 Nov;70(1):1-10 [11766999.001]
  • [Cites] Am J Physiol Cell Physiol. 2005 Apr;288(4):C805-12 [15601754.001]
  • [Cites] Prostate. 2004 May 15;59(3):328-36 [15042609.001]
  • [Cites] Cell Biochem Funct. 2005 Mar-Apr;23(2):109-14 [15565631.001]
  • [Cites] Int J Oncol. 2005 Sep;27(3):687-91 [16077917.001]
  • [Cites] Pharmacol Rev. 1994 Jun;46(2):157-203 [7938165.001]
  • [Cites] J Cell Physiol. 1992 Jan;150(1):1-7 [1309821.001]
  • [Cites] Physiol Behav. 1993 Aug;54(2):229-36 [8372115.001]
  • [Cites] Lancet. 1999 Jan 30;353(9150):391-9 [9950460.001]
  • [Cites] Gut. 1993 Jun;34(6):794-8 [8100206.001]
  • [Cites] Lancet Oncol. 2006 Apr;7(4):301-8 [16574545.001]
  • [Cites] Am J Surg. 2006 Apr;191(4):517-26 [16531147.001]
  • [Cites] Dig Liver Dis. 2006 Feb;38(2):71-7 [16289975.001]
  • [Cites] Int J Oncol. 2005 Aug;27(2):427-32 [16010424.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 May;55(5):425-32 [15565325.001]
  • [Cites] Ann Clin Psychiatry. 1994 Jun;6(2):67-78 [7804391.001]
  • [Cites] Oncol Rep. 2005 Dec;14(6):1593-7 [16273262.001]
  • [Cites] Placenta. 2005 Jul;26(6):484-90 [15950062.001]
  • [Cites] J Biol Chem. 1996 Feb 9;271(6):3141-7 [8621713.001]
  • [Cites] Regul Pept. 2003 Mar 28;111(1-3):145-52 [12609762.001]
  • [Cites] J Leukoc Biol. 1995 Aug;58(2):137-50 [7643009.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Curr Pharm Des. 2005;11(16):2107-17 [15974962.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2004 Jan-Feb;40(1-2):52-6 [14723575.001]
  • [Cites] Eur J Pharmacol. 1995 Oct 15;291(2):209-11 [8566173.001]
  • [Cites] Br J Cancer. 2002 Jan 7;86(1):92-7 [11857018.001]
  • [Cites] Cancer Res. 1993 Nov 15;53(22):5566-8 [8221698.001]
  • [Cites] Cancer Res. 2008 Jul 1;68(13):5487-91 [18593952.001]
  • [Cites] Biochem Biophys Res Commun. 2006 May 19;343 (4):1053-9 [16580628.001]
  • [Cites] BJU Int. 2006 Mar;97(3):634-9 [16469039.001]
  • (PMID = 20306273.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Receptor, Serotonin, 5-HT1B; 0 / Serotonin 5-HT1 Receptor Antagonists; 0 / Serotonin Antagonists; 333DO1RDJY / Serotonin
  •  go-up   go-down


63. Dekter HE, Romijn FP, Temmink WP, van Pelt J, de Fijter JW, Smit NP: A spectrophotometric assay for routine measurement of mammalian target of rapamycin activity in cell lysates. Anal Biochem; 2010 Aug;403(1-2):79-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A spectrophotometric assay for routine measurement of mammalian target of rapamycin activity in cell lysates.
  • The mammalian target of rapamycin (mTOR) is an important mediator in the PI3K/AKT signaling pathway. mTOR is the target of immunosuppressive drugs, such as rapamycin and everolimus, that are used in transplant patients but also for the treatment of various cancers.
  • We have developed a method for mTOR activity measurement in cell lysates that measures the phosphorylation of p70 S6 kinase by an enzyme linked immunosorbent assay (ELISA) protocol.
  • The mTOR activity measurements may be used to show in vivo inhibition in renal allograft patients during everolimus treatment and to study mTOR activity in various (tumor) cell types.
  • [MeSH-minor] Animals. Antigens, CD3 / immunology. Cell Line. Cells, Cultured. Humans. Immunosuppressive Agents / pharmacology. Kidney Transplantation. Leukocytes, Mononuclear / metabolism. Phosphorylation. Ribosomal Protein S6 Kinases, 70-kDa / metabolism. Sirolimus / pharmacology. T-Lymphocytes / immunology. T-Lymphocytes / metabolism. TOR Serine-Threonine Kinases. Transplantation, Homologous

  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20417611.001).
  • [ISSN] 1096-0309
  • [Journal-full-title] Analytical biochemistry
  • [ISO-abbreviation] Anal. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Immunosuppressive Agents; 0 / Intracellular Signaling Peptides and Proteins; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


6
Advertisement
4. Bauer JA, Frye G, Bahr A, Gieg J, Brofman P: Anti-tumor effects of nitrosylcobalamin against spontaneous tumors in dogs. Invest New Drugs; 2010 Oct;28(5):694-702
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-tumor effects of nitrosylcobalamin against spontaneous tumors in dogs.
  • PURPOSE: Given the limited options available to treat canine cancers, the use of companion animals for evaluating new drugs may identify better therapies for veterinary and human oncology.
  • The anti-tumor effects of nitrosylcobalamin (NO-Cbl), an apoptosis-inducing, vitamin B12-based carrier of nitric oxide (NO), was evaluated in four dogs with spontaneous cancer.
  • (1) A 13 year-old female spayed Giant Schnauzer with inoperable thyroid carcinoma and hypercalcemia. (2) A 6 year-old male neutered Golden Retriever with a malignant peripheral nerve sheath tumor (MPNST). (3) A ten yr-old neutered male Bichon Frise with apocrine gland anal sac adenocarcinoma (AGACA). (4) A 7 year-old female spayed Labrador mix with spinal meningioma following partial surgical resection.
  • Tumor regression was measured by physical exam and verified using ultrasound (case 1) and MRI (case 2-4).
  • (1) The Giant Schnauzer demonstrated a 77% reduction in tumor volume after ten weeks of daily NO-Cbl treatment. (2) The Golden Retriever demonstrated a 53% reduction in tumor volume after 15 months of daily NO-Cbl therapy. (3) The Bichon Frise demonstrated a 43% regression of the primary tumor and a 90% regression of an iliac lymph node measured by MRI after 15 months of treatment.
  • After 61 months, the dog currently has stable disease, normal liver enzymes, CBC analysis, and no evidence of toxicity. (4) The Labrador demonstrated complete regression of the residual tumor after 6 months of treatment.
  • CONCLUSION: We have shown previously that NO-Cbl is endocytosed by malignant cells, resulting in intra-tumoral NO release.
  • The use of NO-Cbl capitalizes on the tumor-specific properties of the vitamin B12 receptor and represents a promising anti-cancer therapy.
  • [MeSH-minor] Animals. Antineoplastic Agents / metabolism. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / therapeutic use. Dogs. Dose-Response Relationship, Drug. Female. Magnetic Resonance Imaging. Male. Tumor Burden. Ultrasonography

  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Invest New Drugs. 2011 Oct;29(5):1122
  • [Cites] Eur J Cancer. 2004 Apr;40(6):858-80 [15120042.001]
  • [Cites] J Vet Intern Med. 1988 Jan-Mar;2(1):41-6 [3221354.001]
  • [Cites] Nat Med. 2005 Oct;11(10):1018 [16211022.001]
  • [Cites] J Exp Clin Cancer Res. 2004 Jun;23(2):181-93 [15354401.001]
  • [Cites] J Am Vet Med Assoc. 1991 May 1;198(9):1618-21 [2061177.001]
  • [Cites] J Am Anim Hosp Assoc. 1998 Jan-Feb;34(1):19-25 [9527425.001]
  • [Cites] Vet Radiol Ultrasound. 2001 Sep-Oct;42(5):471-4 [11678572.001]
  • [Cites] J Small Anim Pract. 1999 May;40(5):206-10 [10385862.001]
  • [Cites] J Am Vet Med Assoc. 2006 Aug 15;229(4):542-8 [16910854.001]
  • [Cites] J Vet Intern Med. 2002 Jan-Feb;16(1):100-4 [11822797.001]
  • [Cites] Clin Tech Small Anim Pract. 2007 May;22(2):75-81 [17591293.001]
  • [Cites] Brief Funct Genomic Proteomic. 2005 Jul;4(2):112-28 [16102268.001]
  • [Cites] Anticancer Drugs. 1998 Mar;9(3):239-44 [9625434.001]
  • [Cites] J Nucl Med. 1997 May;38(5):717-23 [9170435.001]
  • [Cites] Semin Vet Med Surg (Small Anim). 1996 Nov;11(4):225-34 [9020576.001]
  • [Cites] Aust Vet J. 2005 Jun;83(6):340-3 [15986909.001]
  • [Cites] Cancer Invest. 2000;18(8):781-92 [11107448.001]
  • [Cites] Mayo Clin Proc. 2000 Jun;75(6):568-80 [10852417.001]
  • [Cites] J Am Vet Med Assoc. 1975 Mar 1;166(5):511-7 [1112759.001]
  • [Cites] Aust Vet J. 2005 Apr;83(4):208-14 [15907038.001]
  • [Cites] J Am Anim Hosp Assoc. 1998 Mar-Apr;34(2):109-12 [9507422.001]
  • [Cites] Vet Pathol. 2004 Jul;41(4):307-18 [15232130.001]
  • [Cites] J Am Anim Hosp Assoc. 1997 Jul-Aug;33(4):307-12 [9204465.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 3;94(13):1010-9 [12096086.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):420-30 [12189384.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):39461-9 [12881518.001]
  • [Cites] J Am Vet Med Assoc. 1995 Apr 1;206(7):1007-9 [7768706.001]
  • [Cites] J Am Vet Med Assoc. 2003 Sep 15;223(6):825-31 [14507100.001]
  • [Cites] J Clin Invest. 1999 Jul;104(2):155-62 [10411544.001]
  • [Cites] J Vet Intern Med. 1994 May-Jun;8(3):236-9 [8064663.001]
  • [Cites] J Am Anim Hosp Assoc. 1995 Jul-Aug;31(4):349-59 [7552669.001]
  • [Cites] In Vivo. 1994 Jan-Feb;8(1):133-43 [8054503.001]
  • [Cites] Mol Cell Biol. 2006 Aug;26(15):5588-94 [16847314.001]
  • [Cites] J Am Vet Med Assoc. 1989 Dec 1;195(11):1580-3 [2599941.001]
  • [Cites] Vet Comp Oncol. 2003 Jun;1(2):94-104 [19379321.001]
  • [Cites] J Neurosurg Anesthesiol. 1994 Apr;6(2):111-5 [8012169.001]
  • [Cites] J Small Anim Pract. 1981 Mar;22(3):119-28 [7230749.001]
  • [Cites] Vet Surg. 2006 Apr;35(3):267-70 [16635006.001]
  • [Cites] Vet Pathol. 1998 May;35(3):223-6 [9598587.001]
  • [Cites] PLoS One. 2007 Dec 12;2(12):e1313 [18074035.001]
  • [Cites] J Exp Clin Cancer Res. 2006 Mar;25(1):97-105 [16761625.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 1;98(3):161-2 [16449674.001]
  • [Cites] J Am Vet Med Assoc. 1987 Sep 15;191(6):720-6 [3679964.001]
  • (PMID = 19557306.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA095020
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitroso Compounds; 0 / nitrosylcobalamin; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


65. Biondo S, Kreisler E, Millan M, Martí-Ragué J, Fraccalvieri D, Golda T, De Oca J, Osorio A, Fradera R, Salazar R, Rodriguez-Moranta F, Sanjuán X: [Long-term results of emergency surgery for colon cancer compared with elective surgery]. Cir Esp; 2007 Aug;82(2):89-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results of emergency surgery for colon cancer compared with elective surgery].
  • [Transliterated title] Resultados a largo plazo de la cirugía urgente y electiva del cáncer de colon. Estudio comparativo.
  • INTRODUCTION: Currently, the mechanisms that worsen the prognosis of complicated colon cancers are still not well known.
  • AIMS: The aim of the present study was to analyze the 5-year efficacy of curative oncological surgery for complicated colon cancer performed in an emergency setting in terms of tumor recurrence and survival compared with elective surgery of uncomplicated tumors.
  • PATIENTS AND METHOD: We performed a prospective observational cohort study in patients who underwent emergency surgery for complicated colon cancer (group 1) and patients who underwent elective surgery (group 2).
  • Exclusion criteria were tumors of less than 15 cm from the anal verge, palliative surgery, and distant metastases.
  • When patients were stratified by TNM stage, worse 5-year cancer-related and disease-free survival rates were observed in group 1 patients with stage II tumors.
  • No differences were found in cancer-related survival rates in stage III patients (P = 0.178).
  • There were no significant differences in overall survival, cancer-related survival or tumor recurrence rates when group 1 was compared with a subgroup of patients in group 2 with factors of poor prognosis.
  • CONCLUSIONS: Complicated colon cancer presents in more advanced stages and had a worse overall long-term prognosis than uncomplicated tumour.
  • Overall survival and cancer-related survival rates similar to those of elective surgery can be achieved in emergency surgery when curative oncological resection is performed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17785142.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


66. Horn L, Backlund M, Johnson DH: Targeting the eicosanoid pathway in non-small-cell lung cancer. Expert Opin Ther Targets; 2009 Jun;13(6):675-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting the eicosanoid pathway in non-small-cell lung cancer.
  • Multiple lines of evidence suggest that cyclooxygenase-2 (COX-2) upregulation is an early event in the development of non-small-cell lung cancer.
  • These findings indicate that an increase in COX-2 expression may play a significant role in the development and growth of lung cancers and possibly with the acquisition of an invasive and metastatic phenotype.
  • Consequently, inhibitors of COX-2 are being studied for their chemopreventative and therapeutic effects in individuals at high risk for lung cancer and patients with established cancers.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thorac Oncol. 2007 Apr;2(4):299-305 [17409801.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1476-81 [17442990.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1306-11 [10728691.001]
  • [Cites] J Clin Invest. 1996 Feb 1;97(3):806-13 [8609238.001]
  • [Cites] Carcinogenesis. 1997 Apr;18(4):795-9 [9111217.001]
  • [Cites] J Clin Invest. 1997 May 1;99(9):2254-9 [9151799.001]
  • [Cites] Cancer Res. 1998 Sep 1;58(17):3761-4 [9731479.001]
  • [Cites] Carcinogenesis. 1998 Aug;19(8):1393-400 [9744535.001]
  • [Cites] J Biol Chem. 2000 May 19;275(20):14838-45 [10809726.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2095-103 [10811675.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):2006-11 [10815926.001]
  • [Cites] J Clin Invest. 2000 Jun;105(11):1589-94 [10841517.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2354-62 [10856094.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] Cancer. 2000 Dec 15;89(12):2637-45 [11135226.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):861-7 [11309334.001]
  • [Cites] Pathol Oncol Res. 2001;7(1):6-13 [11349214.001]
  • [Cites] Dev Cell. 2008 Jun;14(6):818-29 [18539112.001]
  • [Cites] Cancer Res. 2008 Jul 1;68(13):5040-8 [18593902.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6478-86 [18927287.001]
  • [Cites] J Thorac Oncol. 2008 Nov;3(11):1293-300 [18978565.001]
  • [Cites] Lancet. 2008 Nov 15;372(9651):1756-64 [18922570.001]
  • [Cites] BMB Rep. 2008 Nov 30;41(11):808-13 [19017494.001]
  • [Cites] J Thorac Oncol. 2008 Dec;3(12):1454-9 [19057272.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Sep;1(4):223-5 [19138963.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Sep;1(4):241-9 [19138967.001]
  • [Cites] Prostaglandins. 1976 Feb;11(2):381-97 [772759.001]
  • [Cites] Cancer Res. 1989 Feb 15;49(4):853-6 [2492207.001]
  • [Cites] J Clin Oncol. 1993 Sep;11(9):1757-62 [8394881.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):4997-5001 [9823297.001]
  • [Cites] Carcinogenesis. 1998 Dec;19(12):2195-9 [9886578.001]
  • [Cites] Clin Cancer Res. 1999 May;5(5):1001-5 [10353732.001]
  • [Cites] Exp Hematol. 1999 Oct;27(10):1494-502 [10517490.001]
  • [Cites] Carcinogenesis. 2005 Jan;26(1):65-72 [15358636.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):664-70 [15695412.001]
  • [Cites] J Biol Chem. 2005 Feb 4;280(5):3217-23 [15542609.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1071-80 [15713944.001]
  • [Cites] Lung Cancer. 2005 May;48(2):267-73 [15829328.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4191-7 [15930356.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4719-25 [16034047.001]
  • [Cites] Cancer J. 2005 May-Jun;11(3):201-3 [16053662.001]
  • [Cites] Cancer J. 2005 May-Jun;11(3):209-16 [16053664.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):6087-93 [16115954.001]
  • [Cites] Arch Pathol Lab Med. 2005 Sep;129(9):1113-7 [16119982.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6634-40 [16166442.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9455-62 [16230409.001]
  • [Cites] Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37 [16257339.001]
  • [Cites] Pharm Res. 2005 Nov;22(11):1837-53 [16132345.001]
  • [Cites] Gut. 2006 Jan;55(1):115-22 [16118353.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):944-50 [16424029.001]
  • [Cites] J Biol Chem. 2001 Jun 15;276(24):20809-12 [11320076.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3210-8 [11432888.001]
  • [Cites] JAMA. 2001 Aug 22-29;286(8):954-9 [11509060.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2669-74 [11555578.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] Ann Surg. 2002 Mar;235(3):440-3 [11882767.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2443-7 [12114451.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] J Biol Chem. 2002 Dec 27;277(52):50828-33 [12393872.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1604-10 [12738712.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2645-50 [12860939.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3016-24 [12837811.001]
  • [Cites] Ann Oncol. 2003 Nov;14(11):1640-7 [14581272.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jul;36(7):1187-205 [15109566.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1589-97 [15117980.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4266s-4269s [15217972.001]
  • [Cites] Anal Biochem. 2004 Nov 15;334(2):266-75 [15494133.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6759-63 [15501951.001]
  • [Cites] Nature. 1970 Feb 14;225(5233):600-4 [4983971.001]
  • [Cites] Cancer Cell. 2007 May;11(5):395-406 [17482130.001]
  • [Cites] Mol Pharmacol. 2007 Jun;71(6):1715-20 [17412838.001]
  • [Cites] N Engl J Med. 2007 May 24;356(21):2131-42 [17522398.001]
  • [Cites] Lancet Oncol. 2007 Jun;8(6):500-12 [17513173.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5587-93 [17575121.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3266-73 [17664473.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4318-20; author reply 4320 [17878487.001]
  • [Cites] Pharmacol Rev. 2007 Sep;59(3):207-24 [17878511.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1841-54 [17978293.001]
  • [Cites] J Chem Inf Model. 2008 Jan;48(1):179-85 [18052142.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):825-7 [18281650.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):848-55 [18281656.001]
  • [Cites] J Thorac Oncol. 2008 Feb;3(2):107-10 [18303428.001]
  • [Cites] Cancer. 2008 Mar 1;112(5):1114-21 [18219661.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Thorac Oncol. 2008 Apr;3(4):374-9 [18379355.001]
  • [Cites] Clin Cancer Res. 2008 Apr 1;14(7):2088-94 [18381949.001]
  • [Cites] Nat Genet. 2008 Jun;40(6):789-93 [18500342.001]
  • [Cites] Nat Genet. 2008 Jun;40(6):691-2 [18509311.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):2923-7 [16540639.001]
  • [Cites] Invest New Drugs. 2006 May;24(3):203-12 [16096702.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5338-45 [16707460.001]
  • [Cites] Anticancer Agents Med Chem. 2006 May;6(3):209-20 [16712449.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3381-8 [16740761.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9665-72 [17018624.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4825-32 [17050867.001]
  • [Cites] J Biol Chem. 2007 Feb 23;282(8):5356-66 [17186945.001]
  • [Cites] Oncol Rep. 2007 Apr;17(4):823-8 [17342322.001]
  • (PMID = 19409031.001).
  • [ISSN] 1744-7631
  • [Journal-full-title] Expert opinion on therapeutic targets
  • [ISO-abbreviation] Expert Opin. Ther. Targets
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA090949; None / None / / P50 CA090949-07; United States / NCI NIH HHS / CA / CA90949; United States / NCI NIH HHS / CA / P50 CA090949-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cyclooxygenase 2 Inhibitors; 0 / Eicosanoids; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


67. Baek HJ, Lim SC, Kitisin K, Jogunoori W, Tang Y, Marshall MB, Mishra B, Kim TH, Cho KH, Kim SS, Mishra L: Hepatocellular cancer arises from loss of transforming growth factor beta signaling adaptor protein embryonic liver fodrin through abnormal angiogenesis. Hepatology; 2008 Oct;48(4):1128-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular cancer arises from loss of transforming growth factor beta signaling adaptor protein embryonic liver fodrin through abnormal angiogenesis.
  • We have previously demonstrated that 40%-70% of elf(+/-) mice spontaneously develop hepatocellular cancer (HCC) within 15 months, revealing the importance of the transforming growth factor-beta (TGF-beta) signaling pathway in suppressing tumorigenesis in the liver.
  • The current study was carried out to investigate mechanisms by which embryonic liver fodrin (ELF), a crucial Smad3/4 adaptor, suppresses liver tumor formation.
  • Ectopic ELF expression in fetal bovine heart endothelial (FBHE) cells resulted in cell cycle arrest and apoptosis.
  • Further analysis of developing yolk sacs of elf(-/-) mice revealed a failure of normal vasculature and significantly decreased endothelial cell differentiation with embryonic lethality.
  • Immunohistochemical analysis of hepatocellular cancer (HCC) from the elf(+/-) mice revealed an abnormal angiogenic profile, suggesting the role of ELF as an angiogenic regulator in suppressing HCC.
  • Lastly, acute small interfering RNA (siRNA) inhibition of ELF raised retinoblastoma protein (pRb) levels nearly fourfold in HepG2 cells (a hepatocellular carcinoma cell line) as well as in cow pulmonary artery endothelial (CPAE) cells, respectively.
  • CONCLUSION: Taken together these results, ELF, a TGF-beta adaptor and signaling molecule, functions as a critical adaptor protein in TGF-beta modulation of angiogenesis as well as cell cycle progression.
  • Loss of ELF in the liver leads the cancer formation by deregulated hepatocyte proliferation and stimulation of angiogenesis in early cancers.
  • Our studies propose that ELF is potentially a powerful target for mimetics enhancing the TGF-beta pathway tumor suppression of HCC.

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2002 Apr 11;21(16):2593-604 [11971194.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Jun 16;344(4):1216-23 [16650383.001]
  • [Cites] Science. 2003 Jan 24;299(5606):574-7 [12543979.001]
  • [Cites] Biochem Soc Trans. 2003 Feb;31(Pt 1):20-4 [12546646.001]
  • [Cites] Hum Mol Genet. 2003 Apr 1;12 Spec No 1:R97-112 [12668602.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Aug 11;346(4):1150-7 [16782056.001]
  • [Cites] Mol Cell Biol. 2006 Sep;26(18):6983-92 [16943438.001]
  • [Cites] Hepatology. 2007 Aug;46(2):446-55 [17659575.001]
  • [Cites] Oncogene. 2007 Nov 1;26(50):7103-10 [17546056.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Crit Rev Oncog. 1999;10(4):303-60 [10654929.001]
  • [Cites] N Engl J Med. 2000 May 4;342(18):1350-8 [10793168.001]
  • [Cites] J Biol Chem. 2000 Jun 2;275(22):16986-92 [10747927.001]
  • [Cites] J Cell Sci. 2000 Jul;113 ( Pt 13):2331-43 [10852813.001]
  • [Cites] Mol Cell Biol. 2001 Aug;21(15):5122-31 [11438667.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Sep 14;287(1):47-55 [11549251.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1293-300 [11583957.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):153-6 [11668491.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jul 11;306(4):799-804 [12821112.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Jun;130(6):307-19 [15034787.001]
  • [Cites] Hepatology. 2004 Jun;39(6):1517-24 [15185292.001]
  • [Cites] J Hepatol. 2004 Jul;41(1):97-103 [15246214.001]
  • [Cites] Biochem Pharmacol. 2004 Aug 15;68(4):729-38 [15276080.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S27-34 [15508094.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Science. 1988 Apr 8;240(4849):196-9 [2895499.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]
  • [Cites] Nat Genet. 1996 Jul;13(3):343-6 [8673134.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Hum Pathol. 1997 Jun;28(6):698-703 [9191004.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3912-23 [9233801.001]
  • [Cites] J Hepatol. 1997 Nov;27(5):854-61 [9382973.001]
  • [Cites] Hepatology. 1998 Jun;27(6):1554-62 [9620326.001]
  • [Cites] Hepatology. 1998 Jul;28(1):68-77 [9657098.001]
  • [Cites] Oncogene. 1998 Oct 15;17(15):1969-78 [9788440.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):320-4 [9927040.001]
  • [Cites] Oncogene. 1999 Jan 14;18(2):353-64 [9927192.001]
  • [Cites] Liver Int. 2004 Dec;24(6):637-45 [15566516.001]
  • [Cites] Cell Cycle. 2005 Jan;4(1):63-6 [15611645.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4228-37 [15899814.001]
  • [Cites] Semin Liver Dis. 2005;25(2):212-25 [15918149.001]
  • [Cites] Acta Biochim Pol. 2005;52(2):329-37 [15990918.001]
  • [Cites] Science. 2005 Oct 7;310(5745):68-71 [16210527.001]
  • [Cites] Chest. 2005 Dec;128(6 Suppl):585S-590S [16373850.001]
  • [Cites] Oncogene. 2006 Mar 23;25(13):1871-86 [16288220.001]
  • [Cites] Annu Rev Med. 2003;54:17-28 [12359828.001]
  • (PMID = 18704924.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA4285718A; United States / NCI NIH HHS / CA / P01 CA130821; United States / NIDDK NIH HHS / DK / R01 DK56111; United States / NCI NIH HHS / CA / R01 CA106614A; United States / NCI NIH HHS / CA / CA106614-01A2; United States / NCI NIH HHS / CA / R01 CA106614-04; United States / NCI NIH HHS / CA / R01 CA106614; United States / NIDDK NIH HHS / DK / R01 DK056111; United States / NCI NIH HHS / CA / CA130821-01A1; United States / NIDDK NIH HHS / DK / R01 DK58637; United States / NCI NIH HHS / CA / R01 CA106614-01A2; United States / NCI NIH HHS / CA / P01 CA130821-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Microfilament Proteins; 0 / Retinoblastoma Protein; 0 / Transforming Growth Factor beta; 0 / fodrin
  • [Other-IDs] NLM/ NIHMS115900; NLM/ PMC2747753
  •  go-up   go-down


68. Jelski W, Zalewski B, Szmitkowski M: Alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) activity in the sera of patients with liver cancer. J Clin Lab Anal; 2008;22(3):204-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) activity in the sera of patients with liver cancer.
  • In previous investigations we have found elevated levels of ADH, ALDH, and class I ADH activity in liver cancer cells.
  • In this work, the activity of ADH isoenzymes, and ALDH in the sera of patients with liver cancer was measured.
  • Serum samples were taken from 64 patients (28 drinkers, 36 nondrinkers), with liver cancer.
  • A statistically significant increase of class I ADH isoenzymes was found in the sera of cancer patients.
  • The median activity of this class isoenzyme in the total cancer group increased about 51% (2.94 mU/L) in the comparison to the control level (1.43 mU/L).
  • The activity of the class I ADH isoenzyme was significantly higher in the sera of patients with metastatic tumors than with primary cancers.
  • The total ADH activity was significantly higher (44%) among patients with cancer than healthy ones.
  • The activity of class I ADH isoenzymes was elevated only in the serum of patients with metastatic liver cancer.
  • This increase of activity seems to be caused by the enzyme released from liver cancer cells and primary tumors originating in other organs.
  • [MeSH-major] Alcohol Dehydrogenase / blood. Aldehyde Dehydrogenase / blood. Carcinoma, Hepatocellular / enzymology. Liver Neoplasms / enzymology

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18484658.001).
  • [ISSN] 0887-8013
  • [Journal-full-title] Journal of clinical laboratory analysis
  • [ISO-abbreviation] J. Clin. Lab. Anal.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; EC 1.1.1.1 / Alcohol Dehydrogenase; EC 1.2.1.3 / Aldehyde Dehydrogenase
  •  go-up   go-down


69. Sherwood BT, Jones GD, Mellon JK, Kockelbergh RC, Steward WP, Symonds RP: Concomitant chemoradiotherapy for muscle-invasive bladder cancer: the way forward for bladder preservation? Clin Oncol (R Coll Radiol); 2005 May;17(3):160-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant chemoradiotherapy for muscle-invasive bladder cancer: the way forward for bladder preservation?
  • Muscle-invasive bladder cancer is a common malignancy with a high mortality rate.
  • In other tumour models, most notably cervical and anal cancer, radiation and chemotherapy delivered concomitantly have resulted in significant survival advantages.
  • Here, we consider the potential value of this approach in the treatment of invasive bladder cancer.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15900999.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 59
  •  go-up   go-down


70. Schulte T, Kahlke V: [Mass of the pelvis minor--the coloproctological point of view]. Ther Umsch; 2007 Jul;64(7):389-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Raumforderung im kleinen Becken--Sicht des Coloproktologen.
  • It contains the pelvic organs like the inner genital organs of women, the urinary bladder the rectum and parts of the anus.
  • The rectum is the origin of benign and malign tumors.
  • Most frequently you find under these tumors the benign adenoma and hamartoma and the malign like the rectal and anal cancer.
  • The further diagnostic work up and following therapy relates to the histology and the anatomical location of the tumor.
  • [MeSH-major] Anus Neoplasms. Pelvic Neoplasms. Rectal Neoplasms
  • [MeSH-minor] Adult. Colonoscopy. Combined Modality Therapy. Diagnosis, Differential. Endosonography. Humans. Middle Aged. Neoplasm Staging. Postoperative Care. Proctoscopy. Rectum / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17948756.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


71. Devisetty K, Mell LK, Salama JK, Schomas DA, Miller RC, Jani AB, Roeske JC, Aydogan B, Chmura SJ: A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy. Radiother Oncol; 2009 Nov;93(2):298-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy.
  • Using previous dosimetric analysis methods, we identified the volume of bowel receiving 30 Gy (V(30)) correlated with acute gastrointestinal (GI) toxicity in anal cancer patients treated with intensity-modulated radiation therapy and concurrent chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Anus Neoplasms / therapy. Gastrointestinal Tract / drug effects. Gastrointestinal Tract / radiation effects. Radiotherapy, Intensity-Modulated / adverse effects

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19717198.001).
  • [ISSN] 1879-0887
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


72. Cheng YW, Shawber C, Notterman D, Paty P, Barany F: Multiplexed profiling of candidate genes for CpG island methylation status using a flexible PCR/LDR/Universal Array assay. Genome Res; 2006 Feb;16(2):282-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Accurate determination of cytosine methylation status in promoter CpG dinucleotides may provide diagnostic and prognostic value for human cancers.
  • We have developed a quantitative PCR/LDR/Universal Array assay that allows parallel evaluation of methylation status of 75 CpG dinucleotides in the promoter regions of 15 tumor suppressor genes (CDKN2B, CDKN2A, CDKN2D, CDKN1A, CDKN1B, TP53, BRCA1, TIMP3, APC, RASSF1, CDH1, MGMT, DAPK1, GSTP1, and RARB).
  • In a study using 15 promoter regions and seven blinded tumor cell lines, our technology was capable of distinguishing methylation profiles that identified cancer cell lines derived from the same origins.
  • Preliminary studies using 96 colorectal tumor samples and 73 matched normal tissues indicated CpG methylation is a gene-specific and nonrandom event in colon cancer.


73. Stanley M: Prophylactic HPV vaccines. Drugs Today (Barc); 2007 Oct;43(10):737-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The HPV L1 VLP vaccines are immensely important developments in public health and the benefits that they promise are immense, offering the opportunity to prevent, in the long term, 80% of cervical cancers, 60% of vulval cancers and 80% of anal cancers in women.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17987226.001).
  • [ISSN] 1699-3993
  • [Journal-full-title] Drugs of today (Barcelona, Spain : 1998)
  • [ISO-abbreviation] Drugs Today
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  •  go-up   go-down


74. Bean SM, Chhieng DC: Anal-rectal cytology: a review. Diagn Cytopathol; 2010 Jul;38(7):538-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal-rectal cytology: a review.
  • The incidence of invasive anal squamous cell carcinoma, a human papilloma virus (HPV) related cancer, is on the rise, especially in HIV positive men who have sex with men (MSM).
  • Like cervical cancer, anal cancer is associated with precursor lesions detectable on exfoliative cytology as squamous intraepithelial lesions and on biopsy as intraepithelial neoplasia.
  • Anal-rectal cytology screening programs, similar to cervical cytology screening programs, have been developed in an effort to detect and to eradicate precursor lesions prior to progression to invasive squamous cell carcinoma.
  • Either conventional or liquid-based anal-rectal cytology specimens are acceptable, but liquid-based specimens are preferred.
  • A minimum of 2,000-3,000 nucleate squamous cells should comprise adequate specimens.
  • Sensitivity and specificity of a single anal-rectal cytology specimen is comparable with that of a single cervical cytology test, but cytological interpretations do not always correlate with lesion severity.
  • Patients with atypical squamous cells of undetermined significance (ASC-US) or worse should be referred for anoscopy.
  • [MeSH-major] Anal Canal / pathology. Rectum / pathology
  • [MeSH-minor] Anus Neoplasms / diagnosis. Anus Neoplasms / epidemiology. Anus Neoplasms / pathology. Early Detection of Cancer. Humans. Papillomaviridae / physiology. Specimen Handling

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19941374.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 78
  •  go-up   go-down


76. Kreuter A, Potthoff A, Brockmeyer NH, Gambichler T, Stücker M, Altmeyer P, Swoboda J, Pfister H, Wieland U, German Competence Network HIV/AIDS: Imiquimod leads to a decrease of human papillomavirus DNA and to a sustained clearance of anal intraepithelial neoplasia in HIV-infected men. J Invest Dermatol; 2008 Aug;128(8):2078-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod leads to a decrease of human papillomavirus DNA and to a sustained clearance of anal intraepithelial neoplasia in HIV-infected men.
  • Anal intraepithelial neoplasia (AIN), a human papillomavirus (HPV)-associated precursor lesion of anal carcinoma, is highly prevalent in HIV-infected men having sex with men (MSM).
  • Standardized follow-up examinations included high-resolution anoscopy, anal cytology/histology, HPV typing, and DNA load determination for HPV types 16, 18, 31, and 33.
  • A total of 74% (14/19) of the patients remained free of AIN at the previously treated site.
  • During follow-up, 58% of all patients (11/19) developed new anal cytological abnormalities in previously normal, untreated anal regions.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Anus Neoplasms / drug therapy. Carcinoma in Situ / drug therapy. DNA, Viral / drug effects. HIV Infections / complications. Papillomaviridae / genetics

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18273049.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / DNA, Viral; 99011-02-6 / imiquimod
  • [Investigator] Adam A; Schewe K; Weitner L; Aratesh K; Arendt G; Bartz C; Behrens G; Beichert M; Bieniek B; Cordes C; Bochow M; Brockmeyer N; Buchholz B; Bogner JR; Buhk T; Clad A; Dannecker M; Dupke S; von Einsiedel R; Esser S; Faetkenheuer G; Fischer K; Freiwald M; Friebe-Hoffmann U; Fenske S; Funk M; Ganschow R; Gingelmaier A; Glaunsinger T; Goebel FD; Gölz J; Grosch-Wörner I; Haberl A; Hamouda O; Harrer T; Hartmann M; Hartl H; Hölscher M; Hower M; Husstedt IW; Jansen K; Jäger H; Jessen H; Jessen A; Karwat M; Klausen G; Kirchhoff F; Knechten H; Köppe S; Kreuter A; Kuhlmann B; Langer P; Lauenroth-Mai; Lehmacher W; Lehmann M; Levin C; Lübke M; Maschke M; Marcus U; Mauss S; Meyerhans A; Meyer-Olson D; ter Meulen V; Michalik C; Moll A; Mosthaf FA; Mutz A; Neuen-Jacob E; Niehues T; Oette M; Paulus U; Plettenberg A; Potthoff A; Racz P; Racz K; Rasokat H; Rausch M; Reichelt D; Reitter A; Rieke A; Rockstroh J; Salzberger B; Schafberger A; Schauer J; Schlote F; Schmidt B; Schranz D; Scholten S; Schuler C; Schwab M; Schmidt W; Schmidt R; Schwarze S; Siffert W; Skaletz-Rorowski A; Sonnenberg-Schwan U; Sopper S; Spengler U; Staszewski S; Steffan E; Stellbrink HJ; Stoll M; Goecke T; Taubert S; Telschik A; Ulmer A; Ullrich R; Uberla K; Usadel S; Vogel M; Wagner R; Walter H; Warnatz K; Wasem J; Wiesel W; Von Weizsäcker K; Wieland U; Wintergerst U; Wolf E; Wolf H; Wünsche T; Wyen Ch; Zeitz M; Zylka-Menhorn V
  •  go-up   go-down


77. Shepherd BE, Redman MW, Ankerst DP: Does Finasteride Affect the Severity of Prostate Cancer? A Causal Sensitivity Analysis. J Am Stat Assoc; 2008 Dec 1;103(484):1392-1404
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does Finasteride Affect the Severity of Prostate Cancer? A Causal Sensitivity Analysis.
  • In 2003 Thompson and colleagues reported that daily use of finasteride reduced the prevalence of prostate cancer by 25% compared to placebo.
  • These results were based on the double-blind randomized Prostate Cancer Prevention Trial (PCPT) which followed 18,882 men with no prior or current indications of prostate cancer annually for seven years.
  • Enthusiasm for the risk reduction afforded by the chemopreventative agent and adoption of its use in clinical practice, however, was severely dampened by the additional finding in the trial of an increased absolute number of high-grade (Gleason score >/= 7) cancers on the finasteride arm.
  • The question arose as to whether this finding truly implied that finasteride increased the risk of more severe prostate cancer or was a study artifact due to a series of possible post-randomization selection biases, including differences among treatment arms in patient characteristics of cancer cases, differences in biopsy verification of cancer status due to increased sensitivity of prostate-specific antigen under finasteride, differential grading by biopsy due to prostate volume reduction by finasteride, and nonignorable drop-out.
  • Via a causal inference approach implementing inverse probability weighted estimating equations, this analysis addresses the question of whether finasteride caused more severe prostate cancer by estimating the mean treatment difference in prostate cancer severity between finasteride and placebo for the principal stratum of participants who would have developed prostate cancer regardless of treatment assignment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20526381.001).
  • [ISSN] 0162-1459
  • [Journal-full-title] Journal of the American Statistical Association
  • [ISO-abbreviation] J Am Stat Assoc
  • [Language] ENG
  • [Grant] United States / NIDA NIH HHS / DA / R01 DA023879-01; United States / NCI NIH HHS / CA / U10 CA037429; United States / NIDA NIH HHS / DA / R01 DA023879; None / None / / R01 DA023879-01; United States / NCI NIH HHS / CA / CA037429-21
  • [Publication-type] JOURNAL ARTICLE
  • [Publication-country] United States
  •  go-up   go-down


78. Moelans CB, de Weger RA, Monsuur HN, Maes AH, van Diest PJ: Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study. Anal Cell Pathol (Amst); 2010;33(3):165-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study.
  • Ductal carcinoma in situ (DCIS) accounts for approximately 20% of mammographically detected breast cancers.
  • Although DCIS is generally highly curable, some women with DCIS will develop life-threatening invasive breast cancer, but the determinants of progression to infiltrating ductal cancer (IDC) are largely unknown.
  • In the current study, we used multiplex ligation-dependent probe amplification (MLPA), a multiplex PCR-based test, to compare copy numbers of 21 breast cancer related genes between laser-microdissected DCIS and adjacent IDC lesions in 39 patients.
  • In contrast, the average number of alterations in low/intermediate and high-grade IDC was similar, and although EGFR alterations were exclusively found in high-grade IDC compared to low/intermediate-grade IDC, there were generally fewer differences between low/intermediate-grade and high-grade IDC than between low/intermediate-grade and high-grade DCIS.In conclusion, there were no significant differences in copy number for 21 breast cancer related genes between DCIS and adjacent IDC, indicating that DCIS is genetically as advanced as its invasive counterpart.
  • [MeSH-major] Breast Neoplasms / metabolism. Carcinoma, Ductal / metabolism. Nucleic Acid Amplification Techniques


79. Liu S: Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv Drug Deliv Rev; 2008 Sep;60(12):1347-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Receptor-based radiopharmaceuticals are of great current interest in molecular imaging and radiotherapy of cancers, and provide a unique tool for target-specific delivery of radionuclides to the diseased tissues.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bioconjug Chem. 2002 Jul-Aug;13(4):750-6 [12121130.001]
  • [Cites] Bioconjug Chem. 2002 Jul-Aug;13(4):881-6 [12121145.001]
  • [Cites] Bioconjug Chem. 2002 Jul-Aug;13(4):902-13 [12121149.001]
  • [Cites] J Med Chem. 2002 Aug 1;45(16):3458-64 [12139456.001]
  • [Cites] J Am Chem Soc. 2002 Sep 25;124(38):11468-79 [12236761.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Nov;29(11):1529-42 [12397472.001]
  • [Cites] Appl Radiat Isot. 2002 Nov;57(5):749-63 [12433051.001]
  • [Cites] Bioconjug Chem. 2003 Jan-Feb;14(1):3-17 [12526687.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Mar;30(3):463-9 [12569416.001]
  • [Cites] Cancer Biother Radiopharm. 2002 Dec;17(6):641-6 [12537667.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2001 May;1(1):71-93 [12678771.001]
  • [Cites] Chemistry. 2003 May 9;9(9):2053-61 [12740853.001]
  • [Cites] Nucl Med Biol. 2003 Jul;30(5):465-70 [12831983.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):33602-8 [12815046.001]
  • [Cites] J Nucl Med. 1993 Feb;34(2):222-7 [8429340.001]
  • [Cites] Bioconjug Chem. 1993 Jul-Aug;4(4):275-83 [8218484.001]
  • [Cites] J Nucl Med. 1993 Nov;34(11):1953-63 [8229241.001]
  • [Cites] J Nucl Med. 1993 Nov;34(11):1964-74 [8229242.001]
  • [Cites] J Cereb Blood Flow Metab. 1994 Jan;14 Suppl 1:S4-11 [8263070.001]
  • [Cites] J Nucl Med. 1994 Feb;35(2):334-41 [8295007.001]
  • [Cites] Cancer. 1994 Feb 1;73(3 Suppl):769-73 [8306258.001]
  • [Cites] J Nucl Med. 1994 May;35(5):882-9 [8176477.001]
  • [Cites] Bioconjug Chem. 1994 May-Jun;5(3):182-93 [7918738.001]
  • [Cites] Eur J Nucl Med. 1994 Jul;21(7):640-6 [7957350.001]
  • [Cites] Bioconjug Chem. 1994 Nov-Dec;5(6):565-76 [7873659.001]
  • [Cites] Nucl Med Biol. 1995 Jan;22(1):25-30 [7735166.001]
  • [Cites] J Nucl Med. 1995 May;36(5):829-36 [7738660.001]
  • [Cites] Bioconjug Chem. 1995 Mar-Apr;6(2):219-25 [7599265.001]
  • [Cites] J Nucl Med. 1995 Aug;36(8):1384-91 [7629582.001]
  • [Cites] J Nucl Med. 1995 Aug;36(8):1451-5 [7629593.001]
  • [Cites] Nucl Med Biol. 1995 Jul;22(5):643-8 [7581175.001]
  • [Cites] Nucl Med Biol. 1995 Aug;22(6):749-57 [8535335.001]
  • [Cites] J Nucl Med. 1995 Dec;36(12):2306-14 [8523124.001]
  • [Cites] J Nucl Med. 1995 Dec;36(12):2315-25 [8523125.001]
  • [Cites] Bioconjug Chem. 2001 Jan-Feb;12(1):84-91 [11170370.001]
  • [Cites] J Pharm Sci. 2001 Feb;90(2):114-23 [11169528.001]
  • [Cites] Semin Oncol. 2000 Dec;27(6 Suppl 12):74-8 [11226003.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1781-5 [11280722.001]
  • [Cites] Bioconjug Chem. 1990 May-Jun;1(3):222-6 [2096914.001]
  • [Cites] J Nucl Med. 1991 Jul;32(7):1445-51 [2066805.001]
  • [Cites] Bioconjug Chem. 1991 Mar-Apr;2(2):71-6 [1868115.001]
  • [Cites] J Nucl Biol Med. 1991 Jan-Mar;35(1):47-59 [1932176.001]
  • [Cites] Eur J Nucl Med. 1999 Nov;26(11):1511-9 [10552097.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3608-16 [10589778.001]
  • [Cites] Acta Oncol. 1999;38 Suppl 13:75-83 [10612500.001]
  • [Cites] Bioconjug Chem. 2000 Jan-Feb;11(1):113-7 [10639093.001]
  • [Cites] Nucl Med Commun. 1999 Dec;20(12):1093-112 [10664991.001]
  • [Cites] J Nucl Med. 2000 Feb;41(2):309-14 [10688116.001]
  • [Cites] J Nucl Med. 2000 Feb;41(2):315-7 [10688117.001]
  • [Cites] Bioconjug Chem. 2000 Mar-Apr;11(2):292-9 [10725108.001]
  • [Cites] Anticancer Res. 2000 Mar-Apr;20(2A):925-48 [10810378.001]
  • [Cites] Semin Nucl Med. 2000 Jul;30(3):195-208 [10928383.001]
  • [Cites] Bioorg Med Chem Lett. 2000 Sep 18;10(18):2133-5 [10999487.001]
  • [Cites] Eur J Nucl Med. 2000 Sep;27(9):1318-25 [11007513.001]
  • [Cites] J Nucl Med. 2000 Oct;41(10):1704-13 [11038002.001]
  • [Cites] Eur J Nucl Med. 2000 Nov;27(11):1700-7 [11105827.001]
  • [Cites] Nucl Med Commun. 2000 Nov;21(11):1043-50 [11192710.001]
  • [Cites] J Nucl Med. 2001 Feb;42(2):326-36 [11216533.001]
  • [Cites] Bioconjug Chem. 2001 Jan-Feb;12(1):7-34 [11170362.001]
  • [Cites] Bioconjug Chem. 1998 Jan-Feb;9(1):87-93 [9460550.001]
  • [Cites] Nucl Med Biol. 1998 Feb;25(2):117-25 [9468026.001]
  • [Cites] Appl Radiat Isot. 1998 Apr;49(4):295-7 [9519439.001]
  • [Cites] Appl Radiat Isot. 1998 Apr;49(4):309-15 [9519440.001]
  • [Cites] BioDrugs. 2001;15(3):151-62 [11437681.001]
  • [Cites] J Am Chem Soc. 2001 Apr 4;123(13):3135-6 [11457025.001]
  • [Cites] Bioconjug Chem. 2001 Jul-Aug;12(4):554-8 [11459460.001]
  • [Cites] Bioconjug Chem. 2001 Jul-Aug;12(4):559-68 [11459461.001]
  • [Cites] Bioconjug Chem. 2001 Jul-Aug;12(4):624-9 [11459468.001]
  • [Cites] Bioconjug Chem. 2001 Jul-Aug;12(4):630-4 [11459469.001]
  • [Cites] Q J Nucl Med. 2001 Jun;45(2):189-200 [11476170.001]
  • [Cites] Nucl Med Biol. 2001 Jul;28(5):527-39 [11516698.001]
  • [Cites] Eur J Nucl Med. 2001 Oct;28(10):1555-65 [11685500.001]
  • [Cites] Semin Nucl Med. 2001 Oct;31(4):260-77 [11710769.001]
  • [Cites] Bioconjug Chem. 2001 Nov-Dec;12(6):1035-42 [11716697.001]
  • [Cites] Cancer Biother Radiopharm. 2001 Dec;16(6):451-5 [11789022.001]
  • [Cites] Bioconjug Chem. 2002 May-Jun;13(3):530-41 [12009943.001]
  • [Cites] Nucl Med Biol. 2002 Jul;29(5):553-60 [12088725.001]
  • [Cites] Bioconjug Chem. 2002 Jul-Aug;13(4):721-8 [12121126.001]
  • [Cites] Nucl Med Biol. 1999 May;26(4):389-96 [10382842.001]
  • [Cites] Bioconjug Chem. 1999 Jul-Aug;10(4):553-7 [10411450.001]
  • [Cites] Semin Nucl Med. 1999 Jul;29(3):221-36 [10433338.001]
  • [Cites] Eur J Nucl Med. 1999 Aug;26(8):869-76 [10436200.001]
  • [Cites] Eur J Nucl Med. 1999 Aug;26(8):877-86 [10436201.001]
  • [Cites] J Nucl Med. 1999 Jun;40(6):1061-71 [10452325.001]
  • [Cites] Nucl Med Biol. 1999 Jul;26(5):551-4 [10473194.001]
  • [Cites] Nat Biotechnol. 1999 Sep;17(9):897-901 [10471933.001]
  • [Cites] Lancet. 1999 Sep 11;354(9182):931-5 [10489968.001]
  • [Cites] Bioconjug Chem. 1999 Sep-Oct;10(5):803-7 [10502346.001]
  • [Cites] Bioconjug Chem. 1999 Sep-Oct;10(5):884-91 [10502357.001]
  • [Cites] J Inorg Biochem. 2004 Nov;98(11):1874-901 [15522415.001]
  • [Cites] Nucl Med Biol. 2005 Jan;32(1):1-20 [15691657.001]
  • [Cites] Nucl Med Biol. 2005 Jan;32(1):29-38 [15691659.001]
  • [Cites] Neoplasia. 2005 Mar;7(3):271-9 [15799827.001]
  • [Cites] J Med Chem. 2005 Apr 21;48(8):2985-92 [15828837.001]
  • [Cites] J Nucl Med. 2005 Oct;46(10):1707-18 [16204722.001]
  • [Cites] Bioconjug Chem. 2005 Nov-Dec;16(6):1580-8 [16287258.001]
  • [Cites] Mini Rev Med Chem. 2006 Feb;6(2):227-34 [16472190.001]
  • [Cites] Anticancer Res. 2006 Jan-Feb;26(1A):431-4 [16475729.001]
  • [Cites] Bioconjug Chem. 2006 Jul-Aug;17(4):1069-76 [16848417.001]
  • [Cites] Bioconjug Chem. 2006 Sep-Oct;17(5):1294-313 [16984141.001]
  • [Cites] Mol Pharm. 2006 Sep-Oct;3(5):472-87 [17009846.001]
  • [Cites] Org Biomol Chem. 2006 Sep 7;4(17):3350-7 [17036125.001]
  • [Cites] Appl Radiat Isot. 2007 Jan;65(1):70-8 [17011200.001]
  • [Cites] Bioconjug Chem. 2006 Nov-Dec;17(6):1499-507 [17105229.001]
  • [Cites] Bioconjug Chem. 2003 Sep-Oct;14(5):1052-6 [13129412.001]
  • [Cites] Cancer Biother Radiopharm. 2003 Aug;18(4):627-41 [14503959.001]
  • [Cites] Bioconjug Chem. 2003 Nov-Dec;14(6):1231-42 [14624640.001]
  • [Cites] Bioconjug Chem. 2003 Nov-Dec;14(6):1279-88 [14624645.001]
  • [Cites] Inorg Chem. 2003 Dec 29;42(26):8831-7 [14686864.001]
  • [Cites] Bioconjug Chem. 2004 Jan-Feb;15(1):41-9 [14733582.001]
  • [Cites] Nucl Med Biol. 2004 Jan;31(1):11-9 [14741566.001]
  • [Cites] J Med Chem. 2004 Mar 11;47(6):1465-74 [14998334.001]
  • [Cites] Bioconjug Chem. 2004 Mar-Apr;15(2):235-41 [15025518.001]
  • [Cites] Mol Imaging Biol. 2004 Sep-Oct;6(5):350-9 [15380745.001]
  • [Cites] J Nucl Med. 1984 Jan;25(1):42-8 [6427428.001]
  • [Cites] Anal Biochem. 1985 Jul;148(1):249-53 [4037304.001]
  • [Cites] Int J Rad Appl Instrum B. 1986;13(4):311-8 [3098704.001]
  • [Cites] Int J Rad Appl Instrum B. 1986;13(4):479-82 [3793505.001]
  • [Cites] J Nucl Med. 1987 Jan;28(1):83-90 [3794813.001]
  • [Cites] J Nucl Med. 1987 Apr;28(4):495-504 [3572535.001]
  • [Cites] J Nucl Med. 1987 Jul;28(7):1180-6 [2955085.001]
  • [Cites] J Nucl Med. 1989 Jul;30(7):1235-9 [2738704.001]
  • [Cites] Int J Rad Appl Instrum B. 1989;16(8):829-37 [2621118.001]
  • [Cites] Magn Reson Med. 1990 Oct;16(1):57-66 [2123958.001]
  • [Cites] Cancer Res. 1991 Jan 15;51(2):676-81 [1845957.001]
  • [Cites] J Nucl Med. 1990 Dec;31(12):2022-8 [2266401.001]
  • [Cites] Int J Rad Appl Instrum B. 1991;18(1):3-7 [2010303.001]
  • [Cites] Bioconjug Chem. 1990 Jan-Feb;1(1):65-71 [2095206.001]
  • [Cites] Bioconjug Chem. 1990 Mar-Apr;1(2):132-7 [2095211.001]
  • [Cites] Bioconjug Chem. 1991 May-Jun;2(3):180-6 [1932217.001]
  • [Cites] Bioconjug Chem. 1991 May-Jun;2(3):187-94 [1932218.001]
  • [Cites] Int J Rad Appl Instrum B. 1991;18(7):667-76 [1787075.001]
  • [Cites] Bioconjug Chem. 1991 Sep-Oct;2(5):333-6 [1838699.001]
  • [Cites] Bioconjug Chem. 1991 Sep-Oct;2(5):353-66 [1790176.001]
  • [Cites] J Nucl Med. 1992 Apr;33(4):558-69 [1552341.001]
  • [Cites] Int J Rad Appl Instrum B. 1992 Feb;19(2):205-12 [1601674.001]
  • [Cites] Bioconjug Chem. 1992 Mar-Apr;3(2):91-9 [1515475.001]
  • [Cites] Bioconjug Chem. 1992 Jul-Aug;3(4):342-5 [1390990.001]
  • [Cites] Bioconjug Chem. 1992 Sep-Oct;3(5):420-3 [1420441.001]
  • [Cites] Bioconjug Chem. 1992 Nov-Dec;3(6):493-8 [1281432.001]
  • [Cites] Radiology. 1993 Jan;186(1):279-83 [7677974.001]
  • [Cites] J Nucl Med. 1993 Jan;34(1):30-8 [8418268.001]
  • [Cites] J Nucl Med. 1988 Feb;29(2):217-25 [3258025.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Jun;85(11):4025-9 [3375252.001]
  • [Cites] J Nucl Med. 1989 Jan;30(1):25-32 [2642954.001]
  • [Cites] Magn Reson Med. 1988 Oct;8(2):180-90 [3210955.001]
  • [Cites] J Med Chem. 1989 Feb;32(2):433-7 [2913304.001]
  • [Cites] Int J Rad Appl Instrum B. 1989;16(1):57-80 [2715001.001]
  • [Cites] Nucl Med Biol. 2007 Jan;34(1):29-35 [17210459.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jan;101(2):175-83 [16838112.001]
  • [Cites] J Nucl Med. 2007 Feb;48(2):311-8 [17268030.001]
  • [Cites] Dalton Trans. 2007 Mar 28;(12):1183-93 [17353949.001]
  • [Cites] Bioconjug Chem. 2007 Mar-Apr;18(2):438-46 [17341108.001]
  • [Cites] Bioconjug Chem. 2007 Mar-Apr;18(2):530-7 [17373771.001]
  • [Cites] J Med Chem. 2007 May 17;50(10):2527-35 [17458949.001]
  • [Cites] Bioconjug Chem. 2007 May-Jun;18(3):724-30 [17378600.001]
  • [Cites] Bioconjug Chem. 2007 Jul-Aug;18(4):1110-7 [17503761.001]
  • [Cites] Bioconjug Chem. 2007 Jul-Aug;18(4):1266-79 [17579472.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12462-7 [17626788.001]
  • [Cites] J Nucl Med. 2007 Aug;48(8):1327-37 [17631556.001]
  • [Cites] Inorg Chem. 2007 Oct 15;46(21):8988-97 [17784751.001]
  • [Cites] Bioconjug Chem. 2008 Jan;19(1):201-10 [18069778.001]
  • [Cites] Eur J Nucl Med. 1996 Jan;23(1):40-8 [8586100.001]
  • [Cites] J Med Chem. 1996 Mar 29;39(7):1372-82 [8691467.001]
  • [Cites] J Nucl Med. 1996 May;37(5):775-81 [8965144.001]
  • [Cites] J Nucl Med. 1996 Feb;37(2):352-62 [8667076.001]
  • [Cites] J Nucl Med. 1996 Feb;37(2):362-70 [8667077.001]
  • [Cites] Bioconjug Chem. 1996 Mar-Apr;7(2):165-79 [8983338.001]
  • [Cites] Bioconjug Chem. 1996 Mar-Apr;7(2):196-202 [8983341.001]
  • [Cites] Bioconjug Chem. 1996 Mar-Apr;7(2):203-8 [8983342.001]
  • [Cites] Bioconjug Chem. 1996 Jan-Feb;7(1):63-71 [8741992.001]
  • [Cites] Bioconjug Chem. 1996 Jul-Aug;7(4):421-9 [8853455.001]
  • [Cites] Q J Nucl Med. 1996 Sep;40(3):221-33 [8961801.001]
  • [Cites] J Nucl Med. 1997 Jan;38(1):105-11 [8998163.001]
  • [Cites] J Nucl Med. 1997 Jan;38(1):133-8 [8998167.001]
  • [Cites] Nucl Med Biol. 1996 Nov;23(8):957-80 [9004284.001]
  • [Cites] J Med Chem. 1997 Jan 3;40(1):132-6 [9016338.001]
  • [Cites] Bioconjug Chem. 1997 Mar-Apr;8(2):146-54 [9095354.001]
  • [Cites] Eur J Nucl Med. 1997 Apr;24(4):368-71 [9096086.001]
  • [Cites] Semin Nucl Med. 1997 Apr;27(2):165-82 [9144858.001]
  • [Cites] Bioconjug Chem. 1997 May-Jun;8(3):407-15 [9177848.001]
  • [Cites] Q J Nucl Med. 1997 Jun;41(2):63-70 [9203845.001]
  • [Cites] Nucl Med Biol. 1994 Jan;21(1):83-7 [9234268.001]
  • [Cites] Bioconjug Chem. 1997 Sep-Oct;8(5):621-36 [9327124.001]
  • [Cites] Bioorg Med Chem. 1997 Oct;5(10):1925-34 [9370037.001]
  • [Cites] Bioconjug Chem. 2000 May-Jun;11(3):345-51 [10821650.001]
  • [Cites] J Nucl Med. 2000 Jun;41(6):1114-9 [10855644.001]
  • [Cites] Eur J Nucl Med. 2000 Jun;27(6):628-37 [10901448.001]
  • [Cites] Curr Pharm Des. 2000 Jul;6(11):1159-77 [10903388.001]
  • [Cites] Curr Pharm Des. 2000 Sep;6(14):1399-418 [10903400.001]
  • [Cites] Curr Med Chem. 2000 Sep;7(9):971-94 [10911025.001]
  • [Cites] Nucl Med Commun. 1997 Nov;18(11):992-1007 [9423199.001]
  • [Cites] Nucl Med Biol. 1997 Nov;24(8):761-9 [9428603.001]
  • [Cites] J Nucl Med. 1997 Dec;38(12):1934-9 [9430473.001]
  • [Cites] Bioconjug Chem. 1998 Jan-Feb;9(1):72-86 [9460549.001]
  • [Cites] J Med Chem. 1998 Aug 27;41(18):3546-9 [9719608.001]
  • [Cites] Bioconjug Chem. 1998 Sep-Oct;9(5):618-26 [9736496.001]
  • [Cites] J Nucl Med. 1998 Nov;39(11):1944-51 [9829587.001]
  • [Cites] J Nucl Med. 1998 Dec;39(12):2105-10 [9867151.001]
  • [Cites] J Nucl Med. 1999 Jan;40(1):192-7 [9935076.001]
  • [Cites] Q J Nucl Med. 1998 Dec;42(4):250-61 [9973840.001]
  • [Cites] Q J Nucl Med. 1998 Dec;42(4):280-93 [9973843.001]
  • [Cites] J Nucl Med. 1999 Feb;40(2):268-76 [10025834.001]
  • [Cites] Eur J Nucl Med. 1999 Apr;26(4):358-66 [10199941.001]
  • [Cites] Bioconjug Chem. 1999 May-Jun;10(3):431-8 [10346875.001]
  • [Cites] Nucl Med Biol. 1999 Apr;26(3):267-73 [10363797.001]
  • (PMID = 18538888.001).
  • [ISSN] 0169-409X
  • [Journal-full-title] Advanced drug delivery reviews
  • [ISO-abbreviation] Adv. Drug Deliv. Rev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA115883-01A2; United States / NCI NIH HHS / CA / R01 CA115883-02; United States / NCI NIH HHS / CA / R01 CA115883; United States / NCI NIH HHS / CA / CA115883-02; United States / NCI NIH HHS / CA / R01 CA115883-01A2
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Copper Radioisotopes; 0 / Gallium Radioisotopes; 0 / Indium Radioisotopes; 0 / Organotechnetium Compounds; 0 / Radioisotopes; 0 / Radiopharmaceuticals; 0 / Yttrium Radioisotopes
  • [Number-of-references] 284
  • [Other-IDs] NLM/ NIHMS62223; NLM/ PMC2539110
  •  go-up   go-down


80. Damin DC, Rosito MA, Schwartsmann G: Sentinel lymph node in carcinoma of the anal canal: a review. Eur J Surg Oncol; 2006 Apr;32(3):247-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node in carcinoma of the anal canal: a review.
  • AIMS: To review the studies investigating the efficacy of the sentinel lymph node (SLN) procedure in anal canal carcinoma and to evaluate its potential role in guiding a more selective approach for patients with the malignancy.
  • METHODS: A literature search in the PubMed database was preformed using the key words "sentinel lymph node" and "anal cancer".
  • All indexed original articles (except case reports) on the SLN procedure in cancer of the anal canal were analysed.
  • The detection of occult metastases in clinically unsuspicious nodes represents an important improvement in the process of staging these patients, which has not been possible with any other method of diagnosis.
  • Although SLN procedure is still in an early phase of investigation in this type of cancer, it emerges as an objective method to guide individual therapeutic decisions.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma / secondary

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16289647.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 55
  •  go-up   go-down


81. Fucini C, Gattai R, Urena C, Bandettini L, Elbetti C: Quality of life among five-year survivors after treatment for very low rectal cancer with or without a permanent abdominal stoma. Ann Surg Oncol; 2008 Apr;15(4):1099-106
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life among five-year survivors after treatment for very low rectal cancer with or without a permanent abdominal stoma.
  • BACKGROUND: Low rectal cancers situated less than 5 cm from the anal margin are still usually treated with abdomino-perineal excision (APE).
  • Our aim is to compare the quality of life (QOL) of five-year survivors treated for low or very low rectal cancer with an advanced/complex coloanal procedure with the QOL of patients submitted to a standard APE with a definitive abdominal stoma.
  • METHODS: Sixty-two patients, operated on radically for low or very low rectal cancer, who came for their fifth year follow-up visit and were free from cancer, were studied.
  • The patients received the European Organisation for the Research and Treatment of Cancer (EORTC) QOL-30 generic and the CR38 colorectal cancer QOL questionnaires with the recommendation to return the questionnaire to the hospital.
  • CONCLUSIONS: After five years, cancer-free patients operated on for low or very low rectal cancer have a better QOL if a definitive terminal abdominal stoma was avoided.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18181002.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


82. Chen S, Wang L, Duce SL, Brown S, Lee S, Melzer A, Cuschieri A, André P: Engineered biocompatible nanoparticles for in vivo imaging applications. J Am Chem Soc; 2010 Oct 27;132(42):15022-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Iron-platinum alloy nanoparticles (FePt NPs) are extremely promising candidates for the next generation of contrast agents for magnetic resonance (MR) diagnostic imaging and MR-guided interventions, including hyperthermic ablation of solid cancers.
  • We report effective cell internalization of FePt NPs and demonstrate that they can be used for cellular imaging and in vivo MRI applications.
  • This opens the way for several future applications of FePt NPs, including regenerative medicine and stem cell therapy in addition to enhanced MR diagnostic imaging.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Inorg Biochem. 2002 Jul 25;91(1):9-18 [12121757.001]
  • [Cites] J Pharm Biomed Anal. 2002 Apr 15;28(2):323-9 [11929675.001]
  • [Cites] Radiology. 2003 Dec;229(3):838-46 [14657318.001]
  • [Cites] J Am Chem Soc. 2003 Dec 24;125(51):15702-3 [14677934.001]
  • [Cites] Chem Rev. 2004 Jan;104(1):293-346 [14719978.001]
  • [Cites] Mol Imaging. 2004 Jan;3(1):24-32 [15142409.001]
  • [Cites] Magn Reson Imaging. 1995;13(5):661-74 [8569441.001]
  • [Cites] Bioconjug Chem. 1999 Mar-Apr;10(2):186-91 [10077466.001]
  • [Cites] Biomaterials. 2005 May;26(13):1565-73 [15522758.001]
  • [Cites] NMR Biomed. 2004 Nov;17(7):484-99 [15526347.001]
  • [Cites] Nat Mater. 2005 Jun;4(6):435-46 [15928695.001]
  • [Cites] NMR Biomed. 2005 Oct;18(6):383-9 [16013087.001]
  • [Cites] Biochim Biophys Acta. 2005 Sep 30;1745(3):273-86 [16046009.001]
  • [Cites] J Am Chem Soc. 2007 Feb 7;129(5):1428-33 [17263428.001]
  • [Cites] Angew Chem Int Ed Engl. 2007;46(8):1222-44 [17278160.001]
  • [Cites] Small. 2008 Jan;4(1):26-49 [18165959.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Aug 17;60(11):1252-65 [18558452.001]
  • [Cites] Nat Nanotechnol. 2007 Aug;2(8):469-78 [18654343.001]
  • [Cites] J Am Chem Soc. 2008 Sep 3;130(35):11828-33 [18681432.001]
  • [Cites] Macromol Biosci. 2008 Dec 8;8(12):1135-43 [18698581.001]
  • [Cites] Chem Soc Rev. 2009 Feb;38(2):372-90 [19169455.001]
  • [Cites] J Am Chem Soc. 2008 Nov 26;130(47):15811-3 [18983148.001]
  • [Cites] Nat Protoc. 2009;4(3):412-23 [19265800.001]
  • [Cites] Nanomedicine (Lond). 2009 Apr;4(3):305-15 [19331538.001]
  • [Cites] Adv Drug Deliv Rev. 2009 Jun 21;61(6):467-77 [19389434.001]
  • [Cites] Acc Chem Res. 2009 Aug 18;42(8):1097-107 [19476332.001]
  • [Cites] J Am Chem Soc. 2009 Oct 28;131(42):15346-51 [19795861.001]
  • [Cites] Nanomedicine (Lond). 2010 Jan;5(1):89-97 [20025467.001]
  • [Cites] Adv Drug Deliv Rev. 2010 Mar 8;62(3):284-304 [19909778.001]
  • [Cites] Expert Opin Drug Deliv. 2010 Jul;7(7):795-809 [20446858.001]
  • [Cites] Bioconjug Chem. 2002 Jan-Feb;13(1):122-7 [11792187.001]
  • [Cites] Nature. 2003 Mar 6;422(6927):37-44 [12621426.001]
  • (PMID = 20919679.001).
  • [ISSN] 1520-5126
  • [Journal-full-title] Journal of the American Chemical Society
  • [ISO-abbreviation] J. Am. Chem. Soc.
  • [Language] ENG
  • [Grant] United Kingdom / Wellcome Trust / / WT081039
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biocompatible Materials
  • [Other-IDs] NLM/ PMC2962530
  •  go-up   go-down


83. Shin LK, Poullos P, Jeffrey RB: MR colonography and MR enterography. Gastrointest Endosc Clin N Am; 2010 Apr;20(2):323-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The bowel is a common site for pathologic processes, including malignancies and inflammatory disease.
  • Colorectal cancer accounts for 10% of all new cancers and 9% of cancer deaths.
  • A significant decrease in the incidence of colorectal cancer and cancer death rates has been attributed to screening measures, earlier detection, and improved therapies.
  • [MeSH-major] Anal Canal / pathology. Colon / pathology. Colonic Polyps / diagnosis. Colorectal Neoplasms / diagnosis. Inflammatory Bowel Diseases / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Diagnosis, Differential. Humans. Image Interpretation, Computer-Assisted / methods. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • (PMID = 20451820.001).
  • [ISSN] 1558-1950
  • [Journal-full-title] Gastrointestinal endoscopy clinics of North America
  • [ISO-abbreviation] Gastrointest. Endosc. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 108
  •  go-up   go-down


84. Yamada K, Watanabe S, Kita S, Kinoshita M, Hayakawa T, Kakehi K: Determination of Tn antigen released from cultured cancer cells by capillary electrophoresis. Anal Biochem; 2010 Jan 1;396(1):161-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determination of Tn antigen released from cultured cancer cells by capillary electrophoresis.
  • An incomplete elongation of O-glycans in mucins has been found in epithelial cancers, leading to the expression of shorter carbohydrate structures such as Tn antigen (GalNAc-O-Ser/Thr), which has been reported to be one of the most specific human cancer-associated structures.
  • In the present paper, we developed a capillary electrophoresis method for the determination of Tn antigen, and applied the method to the analysis of the expressed Tn antigen on some leukemia and epithelial cancer cells.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / analysis. Electrophoresis, Capillary / methods
  • [MeSH-minor] Acetylgalactosamine / isolation & purification. Humans. Tumor Cells, Cultured. ortho-Aminobenzoates / metabolism

  • Hazardous Substances Data Bank. ANTHRANILIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19699708.001).
  • [ISSN] 1096-0309
  • [Journal-full-title] Analytical biochemistry
  • [ISO-abbreviation] Anal. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Tn antigen; 0 / ortho-Aminobenzoates; 118-92-3 / anthranilic acid; KM15WK8O5T / Acetylgalactosamine
  •  go-up   go-down


85. Gao L, Zhou F, Li X, Yang Y, Ruan Y, Jin Q: Anal HPV infection in HIV-positive men who have sex with men from China. PLoS One; 2010;5(12):e15256
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal HPV infection in HIV-positive men who have sex with men from China.
  • BACKGROUND: Anal HPV infection, which contributes to the development of anal warts and anal cancer, is well known to be common among men who have sex with men (MSM), especially among those HIV positives.
  • However, HIV and anal HPV co-infection among MSM has not been addressed in China.
  • Blood and anal swabs were collected for HIV-1 serological test and HPV genotyping.
  • HIV and anal HPV prevalence were 8.5% and 62.1%, respectively.
  • A strong dose-response relationship was found between HIV seropositivity and multiplicity of HPV genotypes (p<0.001), which is consistent with the observation that anal HPV infection was an independent predictor for HIV infection.
  • CONCLUSIONS: A high prevalence of HIV and anal HPV co-infection was observed in the MSM community in Beijing and Tianjin, China.
  • Anal HPV infection was found to be independently associated with increased HIV seropositivity, which suggests the application of HPV vaccine might be a potential strategy to reduce the acquisition of HIV infection though controlling the prevalence of HPV.
  • [MeSH-major] Anal Canal / virology. Anus Diseases / virology. HIV Infections / complications. Papillomavirus Infections / complications. Papillomavirus Infections / epidemiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Disorders.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2000 Aug;27(4):471-9 [10950374.001]
  • [Cites] Diagn Mol Pathol. 2005 Mar;14(1):39-47 [15714063.001]
  • [Cites] Sex Transm Infect. 2001 Aug;77(4):248-54 [11463923.001]
  • [Cites] J Natl Cancer Inst. 2005 Apr 20;97(8):577-86 [15840880.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Lancet Infect Dis. 2006 Jan;6(1):21-31 [16377531.001]
  • [Cites] Vaccine. 2006 Mar 30;24 Suppl 1:S1-15 [16406226.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1915-27 [17494925.001]
  • [Cites] Sex Transm Infect. 2008 Aug;84(4):306-11 [18385223.001]
  • [Cites] Int J Oncol. 2008 Oct;33(4):777-82 [18813791.001]
  • [Cites] Curr Opin Infect Dis. 2009 Apr;22(2):109-14 [19276878.001]
  • [Cites] J Infect Dis. 2009 Apr 1;199(7):965-73 [19239366.001]
  • [Cites] Sex Transm Infect. 2009 Apr;85(2):148-9 [19153110.001]
  • [Cites] Obstet Gynecol Clin North Am. 2009 Mar;36(1):187-200 [19344856.001]
  • [Cites] AIDS. 2009 Jun 1;23(9):1135-42 [19390418.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):1986-92 [19567510.001]
  • [Cites] Sex Transm Infect. 2009 Sep;85(5):330-5 [19342375.001]
  • [Cites] Sex Transm Infect. 2009 Sep;85(5):354-8 [19351623.001]
  • [Cites] AIDS Educ Prev. 2009 Oct;21(5):430-46 [19842827.001]
  • [Cites] J Acquir Immune Defic Syndr. 2010 Jan;53(1):111-6 [19779357.001]
  • [Cites] J Infect Dis. 2010 Jun 1;201(11):1677-85 [20415595.001]
  • [Cites] Oncology (Williston Park). 2010 Apr 15;24(4):364-9 [20464850.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [Cites] Sex Transm Dis. 2003 Aug;30(8):639-44 [12897686.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):1014-9 [1846314.001]
  • [Cites] Am J Med. 1997 May 5;102(5A):3-8 [9217656.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1386-8 [9358136.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] AIDS. 1998 Jul 9;12(10):1177-84 [9677167.001]
  • [Cites] J Infect Dis. 2004 Dec 15;190(12):2070-6 [15551204.001]
  • [Cites] Obstet Gynecol. 2000 Dec;96(6):879-85 [11084171.001]
  • (PMID = 21151900.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2997781
  •  go-up   go-down


91. Vorkas PA, Poumpouridou N, Agelaki S, Kroupis C, Georgoulias V, Lianidou ES: PIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method. J Mol Diagn; 2010 Sep;12(5):697-704
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Somatic mutations in the PIK3CA gene have been discovered in many human cancers, and their presence correlates to therapy response.
  • The developed methodology was further applied in a selected group of 75 breast cancer patients who underwent Trastuzumab treatment.
  • In the 99 tumor samples (validation group), 12/99 (12.1%) exon 9 mutations and 20/99 (20.2%) exon 20 mutations were found.
  • [MeSH-minor] Base Sequence. Cell Line, Tumor. DNA Primers. Humans. Paraffin Embedding. Polymerase Chain Reaction. Reproducibility of Results. Sequence Analysis, DNA

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 May 25;19(23):2739-44 [10851074.001]
  • [Cites] Breast Cancer Res Treat. 2010 Apr;120(2):409-18 [19418217.001]
  • [Cites] Nat Genet. 2001 Nov;29(3):263-4 [11687795.001]
  • [Cites] Clin Chem. 2003 Jun;49(6 Pt 1):853-60 [12765979.001]
  • [Cites] Science. 2004 Apr 23;304(5670):554 [15016963.001]
  • [Cites] Clin Chem. 2004 Jul;50(7):1156-64 [15229148.001]
  • [Cites] Cancer Cell. 2004 Aug;6(2):117-27 [15324695.001]
  • [Cites] Clin Chem. 2004 Oct;50(10):1748-54 [15308590.001]
  • [Cites] J Invest Dermatol. 2004 Nov;123(5):990-2 [15482489.001]
  • [Cites] Nucleic Acids Res. 1988 Feb 11;16(3):1215 [3344216.001]
  • [Cites] Nucleic Acids Res. 1994 Jul 25;22(14):2760-8 [8052531.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):99-102 [9916799.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7678-81 [15520168.001]
  • [Cites] Cancer Biol Ther. 2004 Aug;3(8):772-5 [15254419.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):802-7 [15647370.001]
  • [Cites] Hum Mutat. 2005 Mar;25(3):322 [15712344.001]
  • [Cites] Cancer Cell. 2005 Jun;7(6):561-73 [15950905.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R609-16 [16168105.001]
  • [Cites] Anal Biochem. 2005 Nov 1;346(1):167-75 [16188219.001]
  • [Cites] Br J Cancer. 2006 Feb 27;94(4):455-9 [16449998.001]
  • [Cites] Am J Clin Pathol. 2006 Oct;126(4):608-15 [16938658.001]
  • [Cites] BMC Cancer. 2006;6:295 [17184525.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3577-84 [17575221.001]
  • [Cites] Pathol Int. 2007 Oct;57(10):664-71 [17803655.001]
  • [Cites] Cancer Cell. 2007 Oct;12(4):395-402 [17936563.001]
  • [Cites] Cancer Lett. 2008 Mar 8;261(1):120-6 [18180098.001]
  • [Cites] Clin Chem. 2008 Apr;54(4):757-60 [18375489.001]
  • [Cites] Biotechniques. 2008 Apr;44(4):577-8 [18476826.001]
  • [Cites] BMC Cancer. 2008;8:142 [18495026.001]
  • [Cites] Nucleic Acids Res. 2008 Jun;36(10):3401-8 [18448472.001]
  • [Cites] Am J Clin Pathol. 2008 Aug;130(2):247-53 [18628094.001]
  • [Cites] Nat Med. 2008 Dec;14(12):1351-6 [19029981.001]
  • [Cites] Cancer Res. 2009 Mar 1;69(5):1851-7 [19223544.001]
  • [Cites] J Clin Oncol. 2009 Mar 20;27(9):1477-84 [19237633.001]
  • [Cites] Nature. 2009 Apr 9;458(7239):725-31 [19279572.001]
  • [Cites] Ann Oncol. 2009 Jun;20(6):1020-5 [19150938.001]
  • [Cites] Med Oncol. 2009;26(3):344-9 [19016009.001]
  • [Cites] Mod Pathol. 2010 Jan;23(1):27-37 [19898424.001]
  • [Cites] Clin Biochem. 2010 Jan;43(1-2):178-85 [19747471.001]
  • [Cites] Anal Chem. 2010 Feb 15;82(4):1546-50 [20085301.001]
  • [ErratumIn] J Mol Diagn. 2013 Sep;15(5):730
  • (PMID = 20616362.001).
  • [ISSN] 1943-7811
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human
  • [Other-IDs] NLM/ PMC2928435
  •  go-up   go-down


92. Kuga Y, Tanaka T, Arita M, Usui Y, Okanobu H, Numata Y, Miwata T, Yoshimi S, Murakami E, Moriya T, Ohya T, Nishida T: [A case of effective chemoradiotherapy using S-1 and CDDP for left inguinal lymph node metastasis of anal canal carcinoma]. Gan To Kagaku Ryoho; 2009 Nov;36(11):1923-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of effective chemoradiotherapy using S-1 and CDDP for left inguinal lymph node metastasis of anal canal carcinoma].
  • We report a case of left inguinal lymph node metastasis of anal canal carcinoma, treated effectively with chemotherapy consisting of S-1 and CDDP combined with radiotherapy.
  • In February 2006, a 76-year-old woman underwent resection of a tumor diagnosed as squamous cell carcinoma of the anal canal.
  • Biopsy was performed, and specimens were shown to include squamous cell carcinoma cells.
  • The metastatic tumor in the lymph node responded well to the treatment and decreased remarkably in size by December 2007.
  • Chemotherapy consisting of S-1 and CDDP concurrent with radiotherapy maybe effective for treating metastatic lymph node metastasis of anal canal carcinoma.
  • [MeSH-major] Anal Canal. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Lymphatic Metastasis

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19920402.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


93. Clifford GM, Franceschi S: Cancer risk in HIV-infected persons: influence of CD4(+) count. Future Oncol; 2009 Jun;5(5):669-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer risk in HIV-infected persons: influence of CD4(+) count.
  • Persons infected with HIV are at increased risk for all cancers known or suspected to have an infectious cause, an effect believed to be primarily mediated by lowered host immunity via the depletion of CD4(+) cells.
  • Whereas Kaposi sarcoma and non-Hodgkin lymphoma were recognised as AIDS-defining illnesses early in the HIV epidemic, the influence of declining CD4(+) count on other infection-related cancers has taken longer to establish, undoubtedly because the association is weaker and the dose-response relationship is less steep.
  • However, following improved survival made possible by combined antiretroviral therapy, declining CD4(+) count starts showing an impact on the natural history of various carcinogenic infections and on the risk for an increasingly wide range of cancers, including Hodgkin lymphoma, cervical, anal and liver cancers.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19519206.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 91
  •  go-up   go-down


94. Abramowitz L, Benabderrahmane D, Bouvet E, Duval X: [Anal condyloma prevalence among HIV infected patients]. Med Mal Infect; 2005 May;35(5):299-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal condyloma prevalence among HIV infected patients].
  • [Transliterated title] Prévalence des condylomes anaux chez les patients infectés par le VIH.
  • BACKGROUND: In the general HIV-infected population, there are few data on the prevalence and risk factors for anal condyloma, precursor lesions for anal cancer.
  • FINDINGS: The 473 (92%) examined patients, consisted of 200 homosexual men, 123 heterosexual men, 150 women; 76% were receiving HAART, HIV-RNA was<50 copies/ml in 60%, mean (+/-SD) CD4 cell count were 484 (+/-274)/mm(3).
  • Overall, 108 (23%) pts had histologically-confirmed anal condyloma (36, 15 and 11% of the respective populations), including 51 (47%) pts with only endoanal localisation.
  • Intraepithelial neoplasia of grade I was noted in 59 patients, of grade II in 10 and of grade III in 2 and an invasive endoanal cancer in 1.
  • In multivariate regression analysis, condyloma independent risk factor were history of gonococcia or syphilis (OR=0.54 (0.29-0.99)), and history of previous anal condyloma (OR=2.05 (1.07-3.92) in homosexual men, history of previous penis condyloma (OR=26.8 (2.3-309.6), and unprotected sexual intercourse (OR=7.5 (2.1-26.3)) in heterosexual men and CD4 cell count below 200/mm(3), (OR=8.9 (1.5-51.6)), receptive anal intercourse (OR=6.7 (1.7-25.8)) and history of previous anal condyloma (OR=25.4 (3.4-188.2)) in women.
  • INTERPRETATION: In the HAART era, systematic screening revealed a high rate of anal condyloma in all HIV positive pts (not only in homosexual men).
  • Anal examination should be proposed systematically to all HIV-infected patients.
  • [MeSH-major] Anus Diseases / epidemiology. Condylomata Acuminata / epidemiology. HIV Infections / complications. Sexual Behavior


95. Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, Jay N, Aboulafia D, Cohn DL, Einstein MH, Saah A, Mitsuyasu RT, Palefsky JM: Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis; 2010 Oct 15;202(8):1246-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Human immunodeficiency virus type 1 (HIV-1)-infected men are at increased risk for anal cancer.
  • Human papillomavirus (HPV) vaccination may prevent anal cancer caused by vaccine types.
  • Men with high-grade anal intraepithelial neoplasia or anal cancer by history or by screening cytology or histology were excluded.
  • The primary end points were seroconversion to vaccine types at week 28, in men who were seronegative and without anal infection with the relevant HPV type at entry, and grade 3 or higher adverse events related to vaccination.

  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - HIV InSite .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J STD AIDS. 2009 Sep;20(9):595-600 [19710329.001]
  • [Cites] Lancet. 2009 Jun 6;373(9679):1949-57 [19493565.001]
  • [Cites] Clin Diagn Lab Immunol. 2003 Jan;10(1):108-15 [12522048.001]
  • [Cites] BMC Infect Dis. 2003 Apr 30;3:6 [12723991.001]
  • [Cites] Am J Obstet Gynecol. 1984 Aug 15;149(8):815-23 [6205589.001]
  • [Cites] Am J Pathol. 1992 Jun;140(6):1345-55 [1318640.001]
  • [Cites] J Clin Microbiol. 1992 Oct;30(10):2539-43 [1328278.001]
  • [Cites] Dis Colon Rectum. 1997 Aug;40(8):919-28 [9269808.001]
  • [Cites] J Infect Dis. 1997 Sep;176(3):625-31 [9291307.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] Sex Transm Dis. 2005 May;32(5):314-20 [15849533.001]
  • [Cites] Clin Diagn Lab Immunol. 2005 Aug;12(8):959-69 [16085914.001]
  • [Cites] Clin Infect Dis. 2005 Oct 1;41(7):1045-8 [16142673.001]
  • [Cites] Vaccine. 2006 Jan 16;24(3):272-9 [16139398.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1915-27 [17494925.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1928-43 [17494926.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1203-11 [18525266.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9 [18614927.001]
  • [Cites] Int J Cancer. 2009 May 15;124(10):2375-83 [19189402.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • (PMID = 20812850.001).
  • [ISSN] 1537-6613
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] ENG
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00513526
  • [Grant] United States / NCI NIH HHS / CA / U01CA121947-01; United States / NCRR NIH HHS / RR / UL1 RR024996; United States / NCRR NIH HHS / RR / UL1 RR024996-01; United States / NCRR NIH HHS / RR / M01 RR000865; United States / NCRR NIH HHS / RR / M01 RR000865-26; United States / NCRR NIH HHS / RR / UL1RR024996; United States / NIAID NIH HHS / AI / K23 AI055038; United States / NCRR NIH HHS / RR / UL1 RR024131; United States / NCI NIH HHS / CA / U01 CA121947-01; United States / NIAID NIH HHS / AI / K23 AI 55038; United States / NIAID NIH HHS / AI / K23 AI055038-01; United States / NCI NIH HHS / CA / CA121947-01; United States / NCRR NIH HHS / RR / UL1 RR024131-01; United States / NCRR NIH HHS / RR / M01-RR00865; United States / NCI NIH HHS / CA / U01 CA121947; United States / NIAID NIH HHS / AI / AI055038-01
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; 0 / Papillomavirus Vaccines
  • [Other-IDs] NLM/ NIHMS285476; NLM/ PMC3118428
  •  go-up   go-down


96. Izawa M, Inoue M, Osaki M, Ito H, Harada T, Terakawa N, Ikeguchi M: Cytochrome P450 aromatase gene (CYP19) expression in gastric cancer. Gastric Cancer; 2008;11(2):103-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytochrome P450 aromatase gene (CYP19) expression in gastric cancer.
  • In the present study, we examined aromatase expression in gastric carcinoma.
  • METHODS: Nineteen specimens of gastric carcinoma were obtained from Japanese patients at the Department of Surgery, Tottori University Hospital, Japan.
  • Nontumoral tissues adjacent to the carcinoma were also available for analysis.
  • Six cell lines derived from human gastric cancers were also used as a model system.
  • [MeSH-minor] Blotting, Western. Estradiol / secretion. Gene Expression. Humans. Immunohistochemistry. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1994 Mar 15;54(6):1580-6 [7511047.001]
  • [Cites] Endocr Relat Cancer. 1999 Jun;6(2):315-24 [10731125.001]
  • [Cites] Jpn J Exp Med. 1978 Feb;48(1):61-8 [209229.001]
  • [Cites] Cancer. 1986 Apr 1;57(7):1376-9 [3948119.001]
  • [Cites] N Engl J Med. 1991 Jan 31;324(5):317-22 [1986290.001]
  • [Cites] J Clin Endocrinol Metab. 1981 Aug;53(2):412-7 [7251819.001]
  • [Cites] Cancer Res. 1991 Jan 1;51(1):381-6 [1846312.001]
  • [Cites] Breast Cancer Res. 2007;9(3):R37 [17555561.001]
  • [Cites] Endocrinology. 2002 Aug;143(8):3162-70 [12130582.001]
  • [Cites] Apoptosis. 1999 Oct;4(5):321-5 [14634335.001]
  • [Cites] Fertil Steril. 2008 May;89(5 Suppl):1390-6 [17662285.001]
  • [Cites] Eur J Surg Oncol. 2007 Mar;33(2):195-201 [17046193.001]
  • [Cites] J Endocrinol. 2002 Jan;172(1):21-30 [11786371.001]
  • [Cites] World J Gastroenterol. 2003 Apr;9(4):665-9 [12679906.001]
  • [Cites] Pathol Res Pract. 1992 Feb;188(1-2):53-60 [1594500.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4889-99 [11134158.001]
  • [Cites] Biol Reprod. 1996 Feb;54(2):287-93 [8788178.001]
  • [Cites] J Steroid Biochem Mol Biol. 2007 Aug-Sep;106(1-5):81-96 [17590327.001]
  • [Cites] Circ Res. 1999 Jun 11;84(11):1285-91 [10364566.001]
  • [Cites] Brain Res Brain Res Rev. 1996 Jun;22(1):1-26 [8871783.001]
  • [Cites] Cell. 2001 Mar 9;104(5):719-30 [11257226.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Jun;128(6):319-24 [12073050.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Apoptosis. 2001 Oct;6(5):353-8 [11483859.001]
  • (PMID = 18595017.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / RNA, Messenger; 4TI98Z838E / Estradiol; EC 1.14.14.1 / Aromatase
  •  go-up   go-down


97. Yasuoka H, Kodama R, Hirokawa M, Takamura Y, Miyauchi A, Sanke T, Nakamura Y: CXCR4 expression in papillary thyroid carcinoma: induction by nitric oxide and correlation with lymph node metastasis. BMC Cancer; 2008;8:274
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXCR4 expression in papillary thyroid carcinoma: induction by nitric oxide and correlation with lymph node metastasis.
  • BACKGROUND: Metastasis to regional lymph nodes is a common step in the progression of cancer.
  • Recent evidence suggests that tumor production of CXCR4 promotes lymph node metastasis.
  • Nitric oxide (NO) may also increase metastatic ability in human cancers.
  • METHODS: Nitrite/nitrate levels and functional CXCR4 expression were assessed in K1 and B-CPAP papillary thyroid carcinoma (PTC) cells after induction and/or inhibition of NO synthesis.
  • RESULTS: Production of nitrite/nitrate and functional CXCR4 expression in both cell lines was increased by treatment with the NO donor DETA NONOate.
  • The NOS inhibitor L-NAME eliminated this increase.
  • NO may induce lymph node metastasis via CXCR4 induction in papillary thyroid carcinoma.
  • [MeSH-major] Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Nitroso Compounds / pharmacology. Receptors, CXCR4 / biosynthesis. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / pathology
  • [MeSH-minor] Cell Line, Tumor. Chemokine CXCL12 / metabolism. Enzyme Inhibitors / pharmacology. Humans. Immunohistochemistry. Lymphatic Metastasis. NG-Nitroarginine Methyl Ester / pharmacology. Nitrates / metabolism. Nitric Oxide / antagonists & inhibitors. Nitric Oxide / biosynthesis. Nitric Oxide / pharmacology. Nitric Oxide Donors / pharmacology. Nitrites / metabolism. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Tyrosine / analogs & derivatives. Tyrosine / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. L-TYROSINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2006 Apr;91(4):1582-5 [16418215.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1201-7 [16489074.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15735-40 [17898181.001]
  • [Cites] J Biol Chem. 2008 Feb 15;283(7):4283-94 [18057003.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] J Immunol. 2001 Mar 1;166(5):3067-74 [11207257.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jan;88(1):408-16 [12519884.001]
  • [Cites] Cell Res. 2002 Dec;12(5-6):311-20 [12528889.001]
  • [Cites] J Biol Chem. 2003 Jun 13;278(24):21631-8 [12690099.001]
  • [Cites] J Exp Med. 2003 Nov 3;198(9):1391-402 [14597738.001]
  • [Cites] Nat Rev Cancer. 2004 Jul;4(7):540-50 [15229479.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):2002-12 [7504210.001]
  • [Cites] Anal Biochem. 1993 Oct;214(1):11-6 [7504409.001]
  • [Cites] Biochem J. 1994 Mar 1;298 ( Pt 2):249-58 [7510950.001]
  • [Cites] J Surg Res. 1996 Jun;63(1):49-52 [8661171.001]
  • [Cites] Chem Res Toxicol. 1996 Jul-Aug;9(5):836-44 [8828918.001]
  • [Cites] Nat Med. 1998 Dec;4(12):1371-6 [9846573.001]
  • [Cites] Cancer Cell. 2004 Nov;6(5):459-69 [15542430.001]
  • [Cites] Mod Pathol. 2005 Aug;18(8):1127-33 [15803188.001]
  • [Cites] J Biol Chem. 2005 Oct 21;280(42):35760-6 [16107333.001]
  • [Cites] J Pathol. 2006 Feb;208(3):439-45 [16278821.001]
  • [Cites] J Exp Med. 2006 Sep 4;203(9):2201-13 [16940167.001]
  • (PMID = 18826577.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / CXCR4 protein, human; 0 / Chemokine CXCL12; 0 / Enzyme Inhibitors; 0 / Nitrates; 0 / Nitric Oxide Donors; 0 / Nitrites; 0 / Nitroso Compounds; 0 / RNA, Messenger; 0 / Receptors, CXCR4; 146724-94-9 / 2,2'-(hydroxynitrosohydrazono)bis-ethanamine; 31C4KY9ESH / Nitric Oxide; 3604-79-3 / 3-nitrotyrosine; 42HK56048U / Tyrosine; V55S2QJN2X / NG-Nitroarginine Methyl Ester
  • [Other-IDs] NLM/ PMC2572635
  •  go-up   go-down


98. Greenlee JE, Clawson SA, Hill KE, Wood BL, Tsunoda I, Carlson NG: Purkinje cell death after uptake of anti-Yo antibodies in cerebellar slice cultures. J Neuropathol Exp Neurol; 2010 Oct;69(10):997-1007
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Purkinje cell death after uptake of anti-Yo antibodies in cerebellar slice cultures.
  • Paraneoplastic cerebellar degeneration accompanying gynecological and breast cancers is characteristically accompanied by a serum and cerebrospinal fluid (CSF) antibody response, termed "anti-Yo," which reacts with cytoplasmic proteins of cerebellar Purkinje cells.
  • Because these antibodies interact with cytoplasmic rather than cell surface membrane proteins, their role in causing Purkinje cell death has been questioned.
  • Cultures were then studied in real time and after fixation for potential uptake of antibody and induction of cell death.
  • Anti-Yo antibodies delivered in serum, CSF, or purified IgG were taken up by viable Purkinje cells, accumulated intracellularly, and were associated with cell death.
  • Normal IgG was also taken up by Purkinje cells but did not accumulate and did not affect cell viability.
  • These findings indicate that autoantibodies directed against intracellular Purkinje cell proteins can be taken up to cause cell death and suggest that anti-Yo antibody may be directly involved in the pathogenesis of paraneoplastic cerebellar degeneration.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuroinflammation. 2009;6:31 [19874605.001]
  • [Cites] Lancet Neurol. 2008 Apr;7(4):327-40 [18339348.001]
  • [Cites] Ann Neurol. 2000 Jan;47(1):9-17 [10632096.001]
  • [Cites] J Neurosci Res. 2000 Mar 15;59(6):788-96 [10700016.001]
  • [Cites] J Neurochem. 2000 Apr;74(4):1613-20 [10737619.001]
  • [Cites] J Immunol Methods. 2000 Sep 21;243(1-2):155-66 [10986413.001]
  • [Cites] Anal Biochem. 2001 Jun 1;293(1):8-15 [11373072.001]
  • [Cites] Brain Res Brain Res Protoc. 2002 Oct;10(2):60-8 [12431704.001]
  • [Cites] Ann Neurol. 1983 Dec;14(6):609-13 [6360029.001]
  • [Cites] Science. 1985 Apr 19;228(4697):346-8 [2580350.001]
  • [Cites] Arch Neurol. 1985 Jul;42(7):690-4 [3925934.001]
  • [Cites] Ann Neurol. 1985 Nov;18(5):592-600 [2416270.001]
  • [Cites] Neurology. 1986 Sep;36(9):1163-8 [3528917.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Jul;84(13):4552-6 [3474619.001]
  • [Cites] Neurology. 1988 Sep;38(9):1380-6 [3045692.001]
  • [Cites] Acta Neurol Scand. 1988 Sep;78(3):210-3 [3227806.001]
  • [Cites] Ann Neurol. 1988 Oct;24(4):559-67 [3239956.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Apr;86(8):2873-7 [2649898.001]
  • [Cites] Brain Res. 1989 Apr 3;483(2):379-83 [2706528.001]
  • [Cites] N Engl J Med. 1990 Jun 28;322(26):1844-51 [2348838.001]
  • [Cites] Neurology. 1990 Jul;40(7):1085-91 [2356009.001]
  • [Cites] Lab Invest. 1991 Mar;64(3):345-51 [2002653.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3451-4 [2014264.001]
  • [Cites] J Neurol Sci. 1991 Nov;106(1):82-7 [1779243.001]
  • [Cites] Neurology. 1992 Oct;42(10):1931-7 [1407575.001]
  • [Cites] Ann Neurol. 1993 Apr;33(4):373-80 [8489208.001]
  • [Cites] Neurology. 1993 Oct;43(10):2049-54 [8413965.001]
  • [Cites] Arch Neurol. 1994 Jun;51(6):555-8 [8198465.001]
  • [Cites] J Neurol Sci. 1994 Dec 20;127(2):153-8 [7707074.001]
  • [Cites] Clin Neurol Neurosurg. 1995 Feb;97(1):101-5 [7788964.001]
  • [Cites] Clin Neurol Neurosurg. 1995 Feb;97(1):95-100 [7788981.001]
  • [Cites] Acta Neuropathol. 1995;89(4):341-5 [7610765.001]
  • [Cites] J Neuroimmunol. 1995 Jul;60(1-2):135-41 [7642741.001]
  • [Cites] Neurology. 1995 Oct;45(10):1937-41 [7478000.001]
  • [Cites] Neuropathol Appl Neurobiol. 1996 Aug;22(4):361-9 [8875471.001]
  • [Cites] Appl Environ Microbiol. 1997 Jun;63(6):2421-31 [9172364.001]
  • [Cites] Exp Neurol. 1998 Jan;149(1):299 [9454640.001]
  • [Cites] Exp Neurol. 2007 Jan;203(1):205-12 [17022974.001]
  • [Cites] J Chem Neuroanat. 1999 Sep;17(1):1-12 [10569235.001]
  • (PMID = 20838245.001).
  • [ISSN] 1554-6578
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / P20 GM103433; United States / NINDS NIH HHS / NS / R21 NS059724; United States / NINDS NIH HHS / NS / R21 NS059724-03; United States / NINDS NIH HHS / NS / R21NS059724
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDR2 protein, human; 0 / Immunoglobulin G; 0 / Nerve Tissue Proteins; 0 / Organic Chemicals; 0 / SYTOX Green
  • [Other-IDs] NLM/ NIHMS241543; NLM/ PMC2959164
  •  go-up   go-down


99. Franceschi S, Lise M, Clifford GM, Rickenbach M, Levi F, Maspoli M, Bouchardy C, Dehler S, Jundt G, Ess S, Bordoni A, Konzelmann I, Frick H, Dal Maso L, Elzi L, Furrer H, Calmy A, Cavassini M, Ledergerber B, Keiser O, Swiss HIV Cohort Study: Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer; 2010 Jul 27;103(3):416-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study.
  • BACKGROUND: The advent of highly active antiretroviral therapy (HAART) in 1996 led to a decrease in the incidence of Kaposi's sarcoma (KS) and non-Hodgkin's lymphoma (NHL), but not of other cancers, among people with HIV or AIDS (PWHA).
  • METHODS: We conducted a record-linkage study between the Swiss HIV Cohort Study and nine Swiss cantonal cancer registries.
  • Incidence of cancers of the anus, liver, non-melanomatous skin, and Hodgkin's lymphoma increased in the early- compared with the pre-HAART period, but not during the late-HAART period.
  • The incidence of all non-AIDS-defining cancers (NADCs) combined was similar in all periods, and approximately double that in the general population.
  • [MeSH-major] Antiretroviral Therapy, Highly Active / adverse effects. Lymphoma, Non-Hodgkin / epidemiology. Neoplasms / epidemiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • HIV InSite. treatment guidelines - Non-ARV Adverse Events .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Bern Open Repository and Information System. Free Full text from BORIS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2008 Sep 2;99(5):800-4 [18665172.001]
  • [Cites] JAMA. 2008 Aug 6;300(5):555-70 [18677028.001]
  • [Cites] AIDS. 2009 Jan 28;23(3):385-93 [19114864.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):884-90 [19114688.001]
  • [Cites] Br J Cancer. 2009 Mar 10;100(5):840-7 [19223894.001]
  • [Cites] Lancet Oncol. 2009 Apr;10(4):321-2 [19350698.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] AIDS. 2009 Oct 23;23(16):2183-90 [19734774.001]
  • [Cites] Lancet Oncol. 2009 Dec;10(12):1152-9 [19818686.001]
  • [Cites] Antivir Ther. 2009;14(8):1065-74 [20032536.001]
  • [Cites] Int J Cancer. 2010 Sep 1;127(6):1437-45 [20049835.001]
  • [Cites] J Biomed Inform. 2001 Dec;34(6):387-95 [12198758.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):371-5 [12556691.001]
  • [Cites] AIDS. 2004 Sep 3;18(13):1835-43 [15316345.001]
  • [Cites] IARC Sci Publ. 1987;(82):1-406 [3329634.001]
  • [Cites] Lancet. 1993 Feb 13;341(8842):441 [8094208.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1997;70:1-492 [9705682.001]
  • [Cites] BMJ. 1999 Jul 3;319(7201):23-4 [10390454.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):861-75 [15516959.001]
  • [Cites] AIDS. 2004 Nov 19;18(17):2285-93 [15577541.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] Arch Intern Med. 2006 Aug 14-28;166(15):1632-41 [16908797.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] AIDS. 2007 Jan 11;21(2):207-13 [17197812.001]
  • [Cites] J Viral Hepat. 2007 Mar;14(3):183-8 [17305884.001]
  • [Cites] Environ Mol Mutagen. 2007 Apr-May;48(3-4):215-23 [16395695.001]
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] AIDS. 2008 Jan 11;22(2):301-6 [18097233.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] J Infect Dis. 2008 Jun 15;197(12):1685-94 [18513155.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1203-11 [18525266.001]
  • [Cites] AIDS. 2008 Oct 18;22(16):2135-41 [18832877.001]
  • (PMID = 20588274.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2920013
  • [Investigator] Battegay M; Bernasconi E; Böni J; Bucher HC; Bürgisser P; Calmy A; Cavassini M; Dubs R; Egger M; Elzi L; Fischer M; Flepp M; Fontana A; Francioli P; Furrer H; Fux CA; Gorgievski M; Günthard HF; Hirsch HH; Hirschel B; Hösli I; Kahlert C; Kaiser L; Karrer U; Kind C; Klimkait T; Ledergerber B; Martinetti G; Martinez de Tejada B; Müller N; Nadal D; Paccaud F; Pantaleo G; Rauch A; Regenass S; Rickenbach M; Rudin C; Schmid P; Schultze D; Schöni-Affolter F; Schüpbach J; Speck R; Taffé P; Telenti A; Trkola A; Vernazza P; Weber R; Yerly S
  •  go-up   go-down


100. Kreuter A, Brockmeyer NH, Weissenborn SJ, Gambichler T, Stücker M, Altmeyer P, Pfister H, Wieland U, German Competence Network HIV/AIDS: Penile intraepithelial neoplasia is frequent in HIV-positive men with anal dysplasia. J Invest Dermatol; 2008 Sep;128(9):2316-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Penile intraepithelial neoplasia is frequent in HIV-positive men with anal dysplasia.
  • These patients have a strongly increased risk of HPV-induced anal cancer and its precursor lesion, anal intraepithelial neoplasia (AIN), and a moderately increased risk for penile cancer.
  • Only limited data exist on penile intraepithelial neoplasia (PIN) in HIV+MSM.
  • [MeSH-major] Anus Diseases / epidemiology. Anus Neoplasms / epidemiology. Carcinoma in Situ / epidemiology. HIV Infections. Homosexuality, Male. Penile Neoplasms / epidemiology






Advertisement